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1 Introduction 
1.1 Acute phase response 
The innate immune response in vertebrates is the first line of host defence which is a 
prerequisite for the induction of acquired immunity. Among the innate immune responses, an 
early set of systemic inflammatory reactions induced by infection or tissue damage are 
referred to acute phase response [1]. This process results in fever and leukocytosis, changes in 
vascular permeability, increases in metabolic responses, and enhancement of non-specific 
host defences. One of the prominent features of the acute phase response is the rapid change 
of plasma levels of a number of proteins, collectively known as acute phase proteins (APP). 
Most of the APPs, named as positive APPs, are fast and dramatically induced during 
inflammatory processes.  However, the synthesis and plasma level of some proteins, notably 
albumin, are decreased, hence these proteins are designated as negative APPs. APPs can 
mediate or inhibit inflammatory processes, function as transport proteins, protease inhibitors 
and participate in tissue repair (Table 1). In particular, several APPs including C-reactive 
protein (CRP) and fibrinogen are used clinically as markers for the detection of an acute 
phase response and for the assessment of its intensity [2]. Principally the APPs are 
synthesized in hepatocytes under the control of certain cytokines secreted by activated 
macrophages and monocytes. Interleukin-1 (IL-1) and IL-6 are the main inflammatory 
mediators regulating the expression of APPs [3, 4]. 
 
Based on the distinct cytokine-dependent induction, APPs can be further divided into two 
groups: type I and type II [5]. Type I proteins are mainly induced by IL-1-like cytokines, 
which comprise IL-1α, IL-1β and TNF-α, including serum amyloid A (SAA), CRP, 
complement C3, haptoglobin, and α1-acid glycoprotein. In contrast to type I proteins, type II 
proteins are induced mainly by IL-6 and its family members LIF, IL-11, OSM, CNTF and 
CT-1. Type II proteins include fibrinogen, α1-antichymotrypsin, α1-antitrypsin, and α2-
macroglobulin (α2M). In general, IL-6 potentiates the induction of type I APPs induced by 
IL-1β or TNF-α i.e. CRP and SAA. By contrast, the IL-6-dependent induction of type II 
APPs such as fibrinogen and α2M is suppressed by IL-1β and TNF-α [6-8]. 
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TABLE 1: Human Acute Phase Proteins 
Proteins whose concentrations increase 
Complement system    Cogulation and fibinolytic system 
   C3     Fibrinogen 
  C4     Plasminogen 
  C9     Tissue plasminogen activator 
Factor B     Urokinase 
  C1 inhibitor    Protein S 
C4b-binding protein    Vitronectin 
  Mannose-binding lectin   Plasminogen-activator inhibitor 1 
  Antiproteases    Transport proteins 
  α1-protease inhibitor    Ceruloplasmin 
  α1-Antichymotrypsin    Haptoglobin 
  Pancreatic secretory trypsin inhibitors  Hemopexin 
  Inter-α-trypsin inhibitors 
  Participants in inflammatory responses  Others 
  Secreted phospholipases A2   C-reactive protein 
  Lipopolysaccharide-binding protein  Serum amyloid A 
  IL-1-receptor antagonist   α1-acid glycoprotein 
GCSF     Fibronectin 
      Angiotensinogen 
Proteins whose plasma concentrations decrease 
  Albumin     Transferrin 
Transthyretin    α2-HS glycoprotein 
α-fetoprotein    Thyroxine-binding globulin 
Insulin-like growth factor I   Factor XII 
 
     (adapted from Gabay et al.  [1])  
  
1.2 IL-1 signalling pathway  
1.2.1 IL-1 family cytokines 
IL-1 plays a central role in the initiation of immune and inflammatory responses in many 
tissues [9]. IL-1 refers to two distinct cytokines, IL-1α and IL-1β. Although they share only 
24% identity in protein sequence, IL-1α and IL-1β fold in a highly similar manner, recognize 
the same receptor, the type I IL-1 receptor, and thus initiate identical signalling cascades [10-
12]. IL-1 receptor antagonist (IL-1ra) and IL-18 can be also included in the IL-1 family on the 
basis of similar gene structure and predicted tertiary structure to those of IL-1β [13]. IL-1ra 
acts as an antagonist to the type I IL-1 receptor, thereby limiting the effects of IL-1 [14]. IL-
18 uses its own receptor but induces signalling events in a remarkably similar way as IL-1. 
IL-18 is an important inflammatory mediator acting alone or in combination with IL-12 on 
Th1 and NK cells to induce IFN-γ production [15]. Recently, six novel members of the IL-1 
family have been identified primarily through homology searches to IL-1 in DNA data bases 
[16, 17]. These proteins are termed IL-1F5 to IL-1F10 but the biological importance of these 
proteins is currently unknown.  
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1.2.2 signalling cascades initiated by IL-1 
IL-1 exerts its effects through binding to type I IL-1 receptor to activate multiple signalling 
cascades including the NF-κB and MAPK pathways [18]. The type I IL-1 receptors contain 
three extracellular Ig-like domains and one intracellular so-called TIR (toll/IL-1R) domain, 
which is conserved among toll-like receptors (TLRs) and IL-1Rs [19, 20]. In contrast, the 
type II receptors lack the cytoplasmic TIR domain, are unable to initiate signal transduction 
and act as decoy receptors [13].  
 
Upon ligand engagement, the IL-1 receptor accessory protein (IL-1RAcp) is recruited to the 
IL-1/IL-1R complex resulting in enhanced binding activity of IL-1/IL-1R (See figure 1.1). 
Subsequently one adaptor molecule MyD88, which contains two protein-interaction domains: 
an amino-terminal death domain (DD) and a carboxy-terminal TIR domain, is recruited to the 
IL-1 receptor complex through the interaction of TIR domains. The death domain of MyD88 
interacts with IRAK4 through a DD-DD interaction, resulting in the association of IRAK1 to 
the receptor complexes. The association of IRAK1 and IRAK4 results in the phosphorylation 
of IRAK1. Once phosphorylated, IRAK1 recruits TRAF6 to the receptor complex. The 
association of IRAK4-IRAK1-TRAF6 causes some conformational change in one or more of 
these factors, leading to disengagement from the receptor complex. The IRAK4-IRAK1-
TRAF6 complex then interacts with another preformed complex consisting of TAK1, TAB1, 
and TAB2. This interaction induces the phosphorylation of TAB2 and TAK1. TAK1, in turn, 
phosphorylates the IKK complex, which consists of two catalytic subunits IKK-α, IKK-β and 
one regulatory subunit IKK-γ (also known as IKK1, IKK2 and NEMO respectively). The 
activated IKK complex then phosphorylates IκB at specific amino-terminal serine residues 
(Ser32 and Ser36 of IκBα ). Phosphorylated IκB undergoes ubiquitinylation by SCF-β-TRCP, 
an E3 ligase, that targets IκB for degradation by the 26S proteasome. This leads to liberation 
of NF-κB from the cytoplasmic NF-κB/IκB complex and allows NF-κB (p65/p50) to 
translocate to the nucleus. Following translocation to the nucleus, NF-κB binds their cognate 
DNA binding sites to regulate the transcription of a large number of target genes. Moreover, 
activation of TAK1 also results in the activation of MAPKs. Although the scenario of IL-1 
signalling pathway shown above is generally accepted, the detailed mechanism for the 
pathway is not completely understood. For instance, how the IKK complex exactly is 
activated upon IL-1 stimulation remains elusive. Apart from TAK1, a variety of potential 
upstream IKK kinases have been proposed, including MEKK1, MEKK2, MEKK3, NIK, 
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TBK1, TPL2, and PKCξ [21, 22]. They all have been shown to activate IKK, and some of 
them can phosphorylate the serine residues in the activation loop of IKK directly in vitro. 
However, gene-targeting studies demonstrate that none of them is indispensable for the 
activation of the IKK complex. 
 
Figure 1.1:  Schematic representation of IL-1 signalling pathway 
1.3 IL-6 signalling pathway 
1.3.1 IL-6 and IL-6-type cytokines 
The family of IL-6-type cytokines consists of IL-6, IL-11, leukaemia inhibitory factor (LIF), 
oncostatin M (OSM), cardiotrophin-1 (CT-1), ciliary neurotrophic factor (CNTF) and 
cardiotrophin-like cytokine (CLC). All these cytokines possess a four long-chain α-helix-
bundle topology [23]. They initiate similar signals from the cell surface to the nucleus to 
activate target genes involved in differentiation, survival, apoptosis and proliferation. The 
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receptor complexes for these cytokines at least contain one common signalling transducing 
receptor chain gp130. Signal transduction involves the activation of JAK tyrosine kinase 
family members, leading to the activation of the STAT transcription factors. Several members 
i.e. IL-6, IL-11 and CNTF first bind specifically to their respective α-receptors. In turn, the 
complex of cytokine and α-receptor efficiently recruits the signalling receptor subunits. But 
α-receptors are not required for the other members to signal. While IL-6 and IL-11 signal via 
gp130 homodimers, the remaining IL-6-type cytokines relay the signalling via heterodimers 
of either gp130 and the LIFR (LIF, CNTF, CT-1 and CLC) or gp130 and the OSMR (OSM) 
(See figure 1.2). Regarding the shared signal transducer gp130, it appears that the IL-6-family 
is still expanding. Recently, IL-27, a heterodimer of p28 and Epstein-Barr virus induced gene 
3 (EBI3) subunits, has been found to activate a signalling cascade through the complex of IL-
27 receptor α (WSX-1) and gp130 [24].  
 
IL-6, the prototypical member of the IL-6-type cytokines, is a pleiotropic cytokine involved in 
the regulation of hematopoiesis, the immune response, and in particular the acute phase 
response [25, 26]. It is produced by many different cells after infection, injury or 
immunological changes [27]. IL-6 is a potent growth factor of multiple myeloma and 
plasmocytoma cells. In contrast, IL-6 inhibits the growth of breast carcinoma cells and 
melanoma cells. The growth of myeloid leukemic cell lines and their differentiation into 
macrophages are also inhibited by IL-6.  IL-6 has pro- as well as anti-inflammatory properties. 
IL-6-/- mice display severely impaired APP production after turpentine but not LPS challenge 
[28, 29]. 
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Figure 1.2:  IL-6-type cytokine receptor complexes  
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1.3.2 JAK-STAT pathway 
The binding of IL-6 to its α-receptor gp80 triggers the dimerization of the signal transducer 
gp130, leading to the formation of a hexamer composed of two IL-6, two gp80 and two gp130 
molecules [30, 31]. Recently a crystallographic analysis clearly shows a hexameric structure 
of the IL-6/gp80/gp130 complex [32]. Receptor dimerization results in the 
autophosphorylation/activation of noncovalently associated Janus-Kinases (JAKs): JAK1, 
JAK2 and TYK2 [33, 34]. Of these, JAK1 plays a predominant role in the IL-6 signalling 
cascade, since in cells lacking JAK1 IL-6 signal transduction is greatly impaired [35, 36]. 
JAKs are intracellular tyrosine kinases with molecular masses of 120-140 kDa (figure 1.3). A 
typical kinase domain, called the JAK homology (JH)-1 domain, is located at the C-terminus. 
It is preceded by a kinase-like domain (JH2), which has no catalytic activity, but regulates the 
activity of the kinase domain [37]. JAKs have been predicted to contain an SH2 domain 
whose function is currently not well understood. The N-terminal region of JAKs comprises a 
FERM (four-point-one, ezrin, radixin, and moesin) domain which is crucial for the interaction 
of JAKs with the box1 and box2 motifs that are located in the membrane-proximal region of 
gp130 [38, 39]. Activated JAKs in turn phosphorylate the tyrosine motifs in the cytoplasmic 
part of gp130, creating the docking sites for STATs. The domain structure of STAT proteins 
comprises from N- to C-terminus an oligomerization domain, a coil-coil domain, a DNA 
binding domain, a linker domain, a SH2 domain and a transactivation domain (figure 1.3) 
[40]. The SH2 domain mediates the binding of STATs to the activated tyrosine motifs within 
gp130. There are six tyrosine residues in the cytoplasmic tail of gp130: Y683, Y759, Y767, 
Y814, Y905, and Y915. In case of IL-6 signalling, STAT3 is recruited to the pYXXQ motifs 
(Y767, Y814, Y905 and Y915) whereas STAT1, is recruited to the more restricted consensus 
sequence pYXPQ (Y905, Y915 within gp130) [41, 42]. Following recruitment to the receptor, 
STATs undergo phosphorylation on a single tyrosine residue (Y701 in STAT1 and Y705 in 
STAT3). Phosphorylated STATs are dimerized through the interaction of their SH2 domains 
[43]. Subsequently, STAT dimers translocate into the nucleus and bind to their cognate 
sequences to activate gene transcription.  
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Figure 1.3: Schematic structures of JAKs and STATs 
In addition to tyrosine phosphorylation, serine phosphorylation has been suggested to 
contribute to the full transcriptional activity of STATs [44, 45]. Furthermore, it has been 
reported that arginine 31 of STAT1 is subject to methylation [46]. These results turned out to 
be wrong [47, 48]. Most recently, it has been shown that STAT3 is acetylated at a single 
amino acid, lysine 685, in response to cytokine stimulation [49, 50]. It appears that this 
modification plays an important role for STATs to form stable dimers and to activate 
transcription. 
 
Apart from the JAK-STAT pathway, IL-6 can also trigger the activation of the MAPK 
cascade (figure 1.4). Dimerization of receptors results in recruitment of SHP2 as a molecular 
adaptor to activate the MAPK pathway [26].Comparing to intensively studied JAK-STAT 
pathway, less is known about the signal transduction events resulting in the activation of 
MAPK pathway. 
Figure 1.4: IL-6 activates both JAK-STAT and MAPK cascades 
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1.4 Regulators of the JAK-STAT signalling pathway 
Dysregulation of IL-6 signalling contributes to the onset and maintenance of several diseases, 
such as rheumatoid arthritis, inflammatory bowel disease, osteoporosis, multiple sclerosis and 
various types of cancer (e.g. multiple myeloma, prostate cancer). The pathways that convey 
signals of IL-6 from the cell surface to the nucleus are tightly controlled by diverse 
mechanisms. After the engagement with each other, both IL-6 and its receptors have been 
found to undergo endocytosis and are probably degraded in the lysosomal compartment [51]. 
Besides endocytosis of the receptor-complex, at least three different classes of negative 
regulators exist to limit the strength and duration of IL-6 signalling. These include protein 
tyrosine phosphatases, such as SHP2 and PTPεC, protein inhibitors of activated STATs 
(PIAS) and the suppressors of cytokine signalling (SOCS) [25, 26].  In addition, a number of 
pro-inflammatory cytokines such as IL-1β and TNF-α have been found to be capable of 
modulating IL-6 signalling. 
 
Figure 1.5: Domain structures of SHP2, PIAS and SOCS. RLD, RING-finger-like Zinc-binding domain;  
SAP, scaffold attachment factor A/B, acinus and PIAS domain; AD, acidic region; S/T, Serine/threonine rich 
region; KIR, kinase inhibitory region, ESS, extended SH2-subdomain. 
 
1.4.1 SHP2 
Reversible phosphorylation of proteins is a key mechanism for signal transduction which is 
regulated by two distinct types of enzymes: protein kinases (PKs), which catalyze 
phosphorylation, and protein phosphatases (PPs), which direct dephosphorylation. To date, 
107 genes were predicted to encode protein tyrosine phosphatases (PTPs) in the human 
genome [52]. Typical PTPs contain a 240-250-amino acid ‘PTP’ domain and can be further 
subdivided into transmembrane, receptor-like (RPTP), and non-transmembrane variants. 
tyrosine phosphataseSH2
SHP2
SH2
SOCS
SH2ESSKIR box
PIAS
RLDSAP AD S/T
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The SH2 domain-containing PTP 2 (SHP2) is a non-transmembrane PTP containing two N-
terminal SH2 domains, a catalytic PTP domain and a C-terminal tail (figure 1.5). Gene-
targeting studies revealed SHP2 to be an essential effector for embryonic development since 
homozygotic deletion of exon 2 or exon 3 in mice causes embryonic lethality. Exon 3-/- mice 
embryos die between E8.5 and E10.5 because of defects in gastrulation and mesodermal 
differentiation. Recently SHP2 mutations were found to cause the inherited disorder Noonan 
syndrome, which is characterized by short stature, facial dysmorphia and cardiac defects [53]. 
 
The crystal structure of SHP2 shows that, in the absence of phosphorylated binding partners, 
the N-terminal SH2 domain fits into the catalytic pocket of the phosphatase domain and 
thereby prevents substrate access [54]. Binding of SH2 domains to phosphorylated motifs of 
receptors or adaptors unfolds the protein and results in dramatic increase in enzymatic activity 
[55-57]. SHP2 can also be activated by phosphorylation of the two tyrosine residues 542 and 
580 within the C-terminal part of the enzyme. Phosphorylated tyrosines interact with the N- 
and C-terminal SH2 domains respectively, relieving the PTP domain from the N-terminal 
SH2 domain-mediated inhibition [58]. 
 
After the engagement of IL-6 to the α-receptor gp80, gp130 is dimerized and phosphorylated 
at multiple tyrosine motifs thus recruiting a number of signalling molecules such as STATs, 
SOCS3 and  SHP2. SHP2 is recruited to the phosphorylated tyrosine 759 motif within gp130, 
which is also the binding site for SOCS3, a feedback inhibitor of the IL-6 signalling pathway. 
The recruitment of SHP2 to the activated gp130 leads to phosphorylation and activation of 
SHP2. Although both SHP2 and SOCS3 are recruited to the same site within  gp130, recent 
data revealed that SHP2 can negatively regulate the IL-6-mediated JAK-STAT pathway 
independently of SOCS3 [59]. Apart from acting as an inhibitor of the IL-6-induced JAK-
STAT pathway, SHP2 has been suggested to be an adaptor for the activation of the MAPK 
pathway. The mutation of tyrosine 759 to phenylalanine within gp130 leads to a dampened 
MAPK cascade suggesting that SHP2 plays an important role in the IL-6-initiated MAPKs 
signalling. However, so far, the exact mechanism how SHP2 mediates the activation of the 
MAPK pathway is not well understood. 
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1.4.2 PIAS  
The mammalian PIAS family is comprised of five members: PIAS1, PIAS3, PIASxα, 
PIASxβ, and PIASy [60]. The PIAS proteins are characterised by a central conserved RING-
finger-like Zinc-binding domain (RLD) and a SAP (scaffold attachment factor A/B, acinus 
and PIAS) domain at the N-terminus (figure 1.5). Initially PIAS1 was identified by yeast two-
hybrid screening using STAT1β as the ‘bait’. The interaction between the PIAS and STATs is 
cytokine-dependent. Each member of the PIAS family has been shown to be able to inhibit 
STAT-mediated gene activation. However, they exert their inhibitory actions on the JAK-
STAT pathway through distinct mechanisms. PIAS1 and PIAS3 inhibit DNA binding activity 
of STAT1 and STAT3, respectively [61, 62]. In contrast, PIASx and PIASy inhibit STAT4- 
and STAT1-dependent transcription without affecting the DNA binding activities of STAT4 
and STAT1 [63, 64]. It seems that PIASx and PIASy function as transcriptional co-repressors 
of STATs, probably by recruiting HDACs and other co-repressor molecules. It is noteworthy 
that PIAS proteins do not always repress transcriptional activity. For instance, PIAS1 has 
been shown to enhance the transcriptional activity of androgen receptor under certain 
conditions [65]. Recently, it has been reported that PIAS proteins possess SUMO E3 ligase 
activity and a variety of transcription factors such as p53, LEF1 and SP-1 have been shown to 
be sumoylated by PIAS proteins [66-68]. Recent studies indicate that STAT1 can also be 
sumoylated by PIAS proteins, but the role of sumoylation in the regulation of STAT1 activity 
is yet unknown [69, 70]. 
 
1.4.3 Suppressors of cytokine signalling (SOCS) 
The prototypical member of the SOCS molecules, cytokine-inducible Src homology 2 (SH2) 
domain-containing protein (CIS), was identified as a feedback inhibitor of cytokine signalling 
a decade ago [71]. Following that report, SOCS1 was identified independently by three 
laboratories [72-74]. To date, the SOCS protein family consists of eight members: CIS and 
SOCS1 to SOCS7 [75-77], each of which has a central SH2 domain; an N-terminal domain of 
variable length and sequence; and a C-terminal 40-amino-acid module called SOCS box 
(figure 1.5). The SOCS box was also found in three other novel protein families:  
— the ankyrin repeat-containing proteins with a SOCS box (ASBs)  
— SPRY domain-containing proteins with a SOCS box (SSBs) and   
— WD40 repeat-containing proteins with a SOCS box [78, 79].  
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Generally, SOCS proteins are present at low levels in unstimulated cells, perhaps because of 
active repression [80-82]. After cytokine stimuli, the mRNA and protein levels are induced 
rapidly with very short half-lives [83]. 
 
Over recent years, the biological function data about the less studied members, SOCS4-
SOCS7, is mounting: SOCS5 has been proposed to inhibit IL-4-induced Th2 differentiation 
by interacting with the cytoplasmic part of IL-4 receptor and inhibiting binding of JAK1 to 
the receptor [84]; SOCS6 binds to insulin receptor and inhibits the activation of Erk1/2, PKB 
and IRS-1 [85]; SOCS7 has been suggested to play a role in maintaining the homeostasis of 
normal cerebrospinal fluid and inhibit STAT3 and STAT5 signalling [86, 87]. Nevertheless, 
the best characterised SOCS family members are CIS, SOCS1, SOCS2 and SOCS3.  
 
SOCS proteins inhibit cytokine signalling through diverse mechanisms. Whereas CIS and 
SOCS2 compete with STATs for the receptor binding sites [71, 88], SOCS1 directly binds to 
the activation loop of JAKs through its SH2 domain to inhibit the JAKs kinase activity [89]. 
By contrast, SOCS3 binds to the activated receptor i.e. Y759 of gp130 [90, 91], Y985 of the 
leptin receptor [92], Y729 of the G-CSF receptor and Y401 of EPO receptor to exert its 
inhibitory function [93, 94]. In addition, for SOCS1 and SOCS3, an N-terminal domain, 
known as kinase inhibitory region (KIR), has also been reported to contribute to the negative 
regulation by acting as a pseudosubstrate for JAKs [95, 96]. Several lines of evidence indicate 
that the conserved SOCS box can interact with elongin B and C to form an E3 ubiquitin ligase 
complex that targets associated proteins for degradation [97, 98]. The fact that SOCS1-
mediated suppression of TEL-JAK2 oncogenic activity requires both the kinase inhibitory 
region (KIR) and the SOCS box demonstrates the importance of these regions [99, 100]. The 
requirement of the SOCS box for the full SOCS1 activity was further supported by the SOCS 
box-deficient SOCS1 ‘knock-in’ mice [101]. Recently, it has been reported that the stability 
of SOCS proteins could be affected by other signalling events. For instance, the interaction of 
elongin C with the SOCS box stablizes SOCS3 protein whereas phosphorylation of tyrosine 
residues within the SOCS box upon various stimuli disrupts the complex and enhances 
proteasome-mediated degradation of SOCS3 [102] 
 
Since the discovery of SOCS proteins, intense studies based on overexpression have shown 
that SOCS proteins can be induced in many cell types by a multitude of cytokines and SOCS 
proteins can regulate numerous cytokine signalling pathways [103]. However, gene-targeting 
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studies suggest SOCS proteins preferentially down-regulate cytokine signalling. For example, 
SOCS1-/- mice die within three weeks, displaying inflammation syndromes in multiple organs 
with significant hematopoietic infiltration and marked reduction in blood lymphocytes 
especially pre-B and B lymphocytes. This phenotype is similar to that observed in wild-type 
mice administrated with IFN-γ [104]. Unequivocal evidence was provided for the inhibitory 
effect SOCS1 on IFN-γ signalling in that SOCS1-/-IFN-γ-/- mice are viable. Of note, although 
previously SOCS1 has been proposed to inhibit the TLR signalling by using SOCS1-/-IFN-γ-/- 
mice [105, 106], recent closer inspection suggests the inhibition of TLR signalling is due to 
lack of IFN-γ [107, 108]. Thus SOCS1 has been deduced to play a primary role in IFN-γ-
mediated signalling. 
 
Disruption of the SOCS3 gene caused embryonic lethality because dysregulated LIF 
signalling leads to defects in the structure of the placenta, rather than defects in erythropoiesis 
as suggested [109]. The physiological roles of SOCS3 were further studied with conditional 
gene targeting mice lacking SOCS3 expression specifically in liver or in macrophages. The 
data has demonstrated a key role for SOCS3 in the regulation of IL-6 signalling [110-112]. 
Although enforced expression of SOCS3 can inhibit the IFN-γ signalling, the regulation of 
IFN-γ signalling was unaltered in the liver of cells lacking SOCS3: The duration and strength 
of IFN-γ-induced STAT1 activation in SOCS3-deficient livers were indistinguishable from 
those of wild-type livers. In contrast, addition of IL-6 led to prolonged activation of STAT1 
and STAT3 in mice bearing SOCS3-deficient livers compared to wild-type littermates. 
Similar results were observed in SOCS3-deficient macrophages. Although SOCS1 and 
SOCS3 are both induced by IL-6 and IFN-γ, and are able to inhibit the responses to these 
cytokines when overexpressed, in vivo data strongly argue that the actions of SOCS proteins 
are not interchangeable but specific. Another interesting piece of these studies is that in 
SOCS3-deficient cells IL-6 can induce a large group of genes, which are typically induced by 
IFN-γ. Through these gene inductions, IL-6 can act as an anti-inflammatory mediator 
suggesting that SOCS3 can regulate not only the quantity but also the quality of cellular 
responses to cytokines [110-112]. 
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1.4.4 Pro-inflammatory cytokines 
The inflammatory cascade underlying the acute phase response is largely controlled by the 
action of different mediators released under inflammatory conditions. Upon activation, 
monocytes and macrophages release a set of pro-inflammatory mediators such as TNF-α and 
IL-1β at the sites of inflammation. These cytokines together with the subsequently induced 
cytokines, for instance IL-6, operate as a network. It has become evident that apart from 
SHP2, PIASs and SOCSs, the JAK-STAT signalling pathway initiated by IL-6 can also be 
regulated by a number of pro-inflammatory mediators such as LPS, TNF-α, and IL-1β as well 
as ionomycin and phorbol ester through a variety of mechanisms. LPS and TNF-α inhibit the 
IL-6-mediated STAT3 activation in macrophages through the induction of SOCS3 [113, 114]. 
Although it is highly controversial, p38 has been proposed to mediate the inhibitory effect of 
LPS, TNF-α, and IL-1β on IL-6 signalling in macrophages as well as in hepatocytes. The 
p38-mediated inhibitory effect does not require de novo protein synthesis [115]. Beisdes p38, 
other MAPK pathways have also been suggested to be involved in the cross-talk between pro-
inflammatory mediators and IL-6 signalling. For example, Erk1/2 MAPKs were found to play 
a crucial role in the inhibitory effect of ionomycin or phorbol ester on IL-6-mediated STAT 
activation [116]. In contrast to p38, Erk1/2-mediated inhibition of pro-inflammatory 
mediators on IL-6 signalling depends on new protein synthesis and the presence of tyrosine 
759 within the cytoplasmic tail of gp130 [117]. NF-κB is another critical mediator for pro-
inflammatory cytokines. It has been shown in hepatocytes that inhibition of IL-6-induced 
α2M and fibrinogen by IL-1β involves the activation of NF-κB. The activated NF-κB 
competes with STAT3 for the overlapping binding sites within α2M promoter and fibrinogen 
promoter, respectively [7, 8]. Most recently, preliminary data from our group suggest that 
after IL-1β stimulation, p65 can form a complex with STAT3 in hepatocytes in an IKKβ-
dependent manner [Albrecht et al. unpublished data]. Further studies are needed to clarify the 
significance of this complex in the cross-talk between IL-6 and IL-1β. 
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1.5 Aims of this study 
SOCS3 is a classic feedback inhibitor for the IL-6 signalling pathway. Although the role of 
SOCS3 protein in modulating cytokine signalling has been extensively studied, less is known 
about the mechanisms that control SOCS3 gene expression. Therefore, this study has focused 
on the regulation of IL-6-induced SOCS3 expression. It has already been reported that SOCS3 
induction is regulated at the transcriptional level in a STAT-dependent manner [118]. 
Recently, Sp3 has been implicated in the regulation of basal as well as IL-6-induced SOCS3 
expression [119] and Egr-1 has been shown to mediate the LPS-induced SOCS1 induction 
[120]. In addition, evidence has been presented that the SOCS3 promoter can be regulated by 
the transcriptional repressor GFI-1B [80]. Moreover, several lines of evidence suggest that the 
p38 pathway is involved in the induction of SOCS3 [121, 122].  
1.5.1 Regulation of IL-6-induced SOCS3 expression by IL-1β 
Although SOCS3 is a cytoplasmic protein, it shares some common features with type II 
APPs: both SOCS3 and type II APPs are rapidly and strongly induced after infection; they are 
induced mainly by IL-6 and most of them are synthesized in the liver. SOCS3 plays an 
essential role in regulating inflammation, allergy and homeostasis by its ability to influence a 
variety of cytokine signalling pathways. It is well documented that IL-1β and TNF-α 
antagonize IL-6-induced type II APP expression such as as α2M and fibrinogen. Thus, it is 
attractive to speculate that IL-6-induced SOCS3 is regulated by IL-1β in a similar way. To 
test this hypothesis, the concerted regulation of SOCS3 expression by IL-6 and IL-1β has 
been investigated in greater detail. 
1.5.2 Importance of IL-6 on the SOCS3 expression in vivo  
The inflammatory response is tightly controlled by multiple cytokines. Many reports have 
indicated that SOCS3 is induced in vitro by various inflammatory and anti-inflammatory 
STAT-activating cytokines such as IL-6, IL-12, IFN-γ and IL-10. In turn, SOCS3 negatively 
regulates those cytokines’ actions. Furthermore, SOCS3 has also been shown to be induced 
by IL-1β , TNF-α, CpG as well as LPS although the function of SOCS3 on these pathways is 
currently not well understood. Whether the in vitro data really reflects the physiological 
relevance remains unclear. So far, the individual contribution of cytokines or inflammatory 
mediators on SOCS3 induction during the inflammatory processes has not been studied. 
Among those cytokines, IL-6 is a key player in the regulation of inflammatory processes. IL-
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6-/- mice display a severely impaired APP induction and anti-inflammatory activities. Is IL-6 
also essential for the SOCS3 induction in vivo? Thus, one specific aim of this study was to 
assess the importance of IL-6 for the SOCS3 induction during the inflammation processes in 
vivo. 
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2 Materials and Methods 
2.1 Chemicals   
All chemicals for buffers were of p.a. grade. The enzmyes were mainly from New England 
Biolabs (Frankfurt/Main, Germany) and Roche (Mannheim, Germany). 
2.2 Radiochemicals 
[α32p]ATP  Hartmann Analytic GmbH (Braunschweig, Germany) 
2.3 Oligonucleotides 
All oligonucleotides were obtained from MWG-Biotech (Ebersberg, Germany) except the 
primers for real-time PCR that were purchased from PE Applied Biosystems (Darmstadt, 
Germany). 
2.4 Antibodies and cytokines 
Antibodies 
anti-SOCS-3 Rabbit polyclonal antibody against SOCS-3 for 
immunoprecipitation supplied by James A. Johnston 
(Belfast, Northern Ireland) 
anti-SOCS-3 (M-20) Goat polyclonal antibody against SOCS-3 for Western 
blotting from Santa Cruz  (Cat. No: SC-7009) 
anti-IκB Rabbit polyclonal antibody, New England Biolabs (Cat 
No: 9242) 
anti-STAT1 (Tyr701)  Rabbit polyclonal antibody, Cell Signalling (Cat. No: 
91715) 
anti-STAT1 (Ser727) Rabbit polyclonal antibody, Upstate Laboratories (Cat. 
No: 06-802) 
anti-STAT1 Rabbit polyclonal antibody, Cell signalling (Cat. No: 
S21120) 
anti-STAT3 (Tyr705) Rabbit monoclonal antibody, Cell Signalling (Cat. No: 
612356) 
anti-STAT3 Mouse monoclonal antibody, Cell signalling (Cat. No: 
610189) 
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anti-p38 Rabbit polyclonal antibody, Cell signalling (Cat. No: 
9214) 
anti-active p38 Rabbit polyclonal antibody, Promega (Cat. No: V1211) 
anti-P65 (C-20) Rabbit polyclonal antibody, Santa Cruz (Cat. No: SC-
372) 
anti-c-Jun (Phosphorylated)  Rabbit polyclonal antibody, Santa Cruz 
Rabbit anti goat-IgG    Polyclonal antibody, DAKO, Denmark 
Goat anti rabbit-IgG    Polyclonal antibody, DAKO, Denmark 
Rabbit anti mouse-IgG   Polyclonal antibody, DAKO, Denmark 
HRP-coupled streptavidin  Polyclonal antibody, DAKO Denmark 
 
Cytokines 
Recombinant human IL-1β   Roche (Mannheim, Germany) 
Recombinant human IL-6  Prepared as described [123] 
Recombinant EPO kind gift from Drs. B. Hilger and K. H. Sellinger (Roche 
Applied Science) 
2.5 Reagents for cell culture 
DMEM/nut-mix-F12 medium   Gibco, Eggenstein 
OPTIMEM medium     Gibco, Eggenstein 
Trypsin/EDTA (0.05%Trypsin/0.02%EDTA) Biochrom, Berlin 
FCS (fetal calf serum)    Cytogen, Berlin 
Penicillin/Streptomycin    Gibco, Eggenstein 
2.5.1 Eukaryotic cells and the culture 
HepG2   adherent human hepatoma cell (ATCC, CRL1651) 
HepG2-IκB(S/A) HepG2 cells stably transfected with IκB(S/A) construct 
 
Human hepatoma cells HepG2 and HepG2-IκB(S/A) were grown in DMEM/nut mix F12 
supplemented with 10%  fetal calf serum, streptomycin (100 mg/L), and penicillin (60 mg/L). 
The cell culture plates were incubated at 37°C in a humidified 5% CO2 incubator. For 
subculturing the cells, cells were washed with PBS twice and treated with tyrpsine-EDTA for 
1 min. Afterwards, cells were diluted appropriately. For long-term storage of cells, the cells 
were frozen in liquid nitrogen at -180°C.  
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PBS: 
0.2 M  NaCl 
2.5 mM KCl 
8.0 mM Na2HPO4 
 1.5 mM KH2PO4 
pH 7.4 
2.5.2 Prokaryotic cells and the culture 
E. coli JM-83, JM110 and XL1-blue were grown in LB-medium supplemented with 100 
µg/ml antibiotic (Ampicillin or Kanamycin) and incubated at 37°C with shaking. For the 
storage of transformed E. coli, cells were stored in LB-medium with 20% Glycerine at -80°C. 
 
LB medium: 
 10 g/l NaCl 
 10 g/l Bactotrypton (Difco) 
 5  g/l Yeast Extract (Difco) 
 
LB plates:  
15 g/l Agar (in LB-Medium) 
2.5.3 Preparation of calcium competent E. coli cells 
E.coli-strain JM83 was grown in 500 ml of SOB medium at 16°C on the platform shaker for 
about 72 h until an optical density of 0.6 (OD600nm) was reached. The cultures were distributed 
to 50 ml sterile tubes and incubated on ice for 10 min then centrifuged for 15 min at 6000 rpm 
at 4°C. Pelleted cells were resuspended in 25 ml of TB buffer and centrifuged again. The 
bacterial sediments were resuspended in 4 ml TB buffer and incubated on ice for 10 min. 
DMSO was added to the resuspended bacteria up to 7.5% final concentration. The tubes were 
chilled on ice for another 10 min. Finally, aliquots of the competent cells were frozen 
immediately in liquid nitrogen. After that, cells were stored at -80°C. 
 
 
SOB-Medium (1000 ml): 
   20 g/l Bactotrypton (Difco) 
   5 g/l Yeast extract (Difco) 
   0.5 g/l NaCl 
   10 ml 0.25 M KCl 
   5 ml 2 M MgCl2 
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TB-buffer: 
   250 mM KCl 
   10 mM PIPES (PH6.7) 
   15 mM CaCl2 
   55 mM MnCl2 
   Sterilized by filtration 
2.6 Plasmids 
pGL3-SOCS3 SOCS-3 reporter construct spanning from –511 to +929 of the 
murine SOCS-3 promoter region fused to the firefly luciferase 
gene (kindly provided by Shlomo Melmed, Los Angeles, CA) 
pRC/CMV-EG(YYYYYY) expression vector for chimeric receptor encoding for the 
extracellular part of EPO receptor and the intracelluar part of 
gp130 
IκBα(S/A) expression vector encoding for an IκBα mutant, where serine 32 
and 36 have been mutated to alanine to avoid phosphorylation 
and subsequent degradation of IκBα (Upstate Laboratories) 
SIE-tk-Luc containing two copies of STAT consensus binding sequence 
from the c-fos promoter upstream of a thymidine kinase minimal 
promoter fused to the firefly luciferase gene (Kind gift from 
Hugues Gascan, Angers, France) 
pCR3lacZ  encoding for the β-galactosidase (Promega, Madison, WI) 
pSUPER  OligoEngine (Seattle, Washington, USA) 
pSUPER-SOCS-3 construct containing siRNA against human SOCS-3, For 
pSUPER-SOCS-3 cloning, 5’- 
GATCCCCGACCCAGTCTCGGGACCAAGAATTCAAGAG
ATTCTTGGTCCCAGACTGGGTCTTTTTGGAAA-3’ and 5’-
AGCTTTTCCAAAAAGACCCAGTCTGGGACCAAGAATC
TCTTGAATTCTTGGTCCCAGACTGGGTCGGG-3’ were 
used. 
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2.7 Methods of molecular biology  
2.7.1 Plasmid transformation into CaCl2 competent E. coli cells  
Frozen cell aliquots were thawed on ice and gently mixed by flicking the tube. Plasmid or 
DNA in total volume of 5 µl or 10 µl of a ligation reaction mixture was added to the 
competent cells and incubated on ice for 10 min. The cells were then heat-shocked at 42°C for 
90 sec and then immediately placed on ice for 2 min. Following the addition of 400 µl of LB-
medium, cells were incubated at 37°C for 30 min. Cells were plated on LB-agar plates 
containing appropriate antibiotics for the selection of strains and plasmids. Different volumes 
of cells were spread in order to obtain single colonies on the plate. Plates were incubated 
overnight at 37°C. 
2.7.2 Restriction digestion of plasmid DNA 
Restriction digestion was carried out according to the standard protocol [124]. Typically 2-10 
µg DNA was digested using 1×optimal buffer and 1 µl enzyme in a 20 µl volume, and 
incubated at 37°C for 1 h. Restriction digestion was analyzed by agarose gel electrophoresis. 
2.7.3 Agarose gel electrophoresis 
Agarose gel electrophoresis (non-denaturing) 
After restriction digestion, the DNA fragments were separated by 1% agarose gel (dissolved 
in 1×TAE and 0.1 ng/ml ethidium bromide) electrophoresis. DNA bands were visualised by 
illumination with UV light and photographed. 
   
6 x DNA loading buffer: 
  15 % Glycerol 
  0.25 % Bromphenol blue 
  0.25 % Xylen cyanol blue 
 
50 x TAE: 
 2 M Tris base  
 1 M Acetic acid 
 50 mM EDTA pH 8.0  
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Running buffer: 
 1 x TAE 
 
Agarose gel electrophoresis (denaturing) 
For the separation and visualisation of total RNA, denaturing agarose gel electrophoresis was 
performed. 10 µg RNA was mixed with 32 µl denaturing buffer and incubated at 65°C for 5 
min. RNA was subjected to electrophoresis on a 1% denaturing agarose gel at 170 V for 2 h.  
 
1 % agarose denaturing gel:     Denaturing buffer: 
 
0.2  M  formaldehyde    20  mM  MOPS  
20  mM  MOPS     1  mM  EDTA 
1  mM  EDTA     2.2  M  formaldehyde 
5  mM  Na-acetate, pH 7.0   50%  formamide, bromphenol blue 
4  mM  Na-acetate, pH 7.0 
2.7.4 DNA purification from agarose gels 
The DNA band of interest was excised and weighted in a 1.5 ml eppendorf tube. The 
purification was performed with Qiaquick Gel extraction Kit according to the manufactuer´s 
instruction (Qiagen, Hilden, Germany). The DNA was dissolved in appropriate volume of 
chromatography water and store at -20°C. 
2.7.5 DNA ligation 
After the vector and the insert DNA have been prepared for ligation, the concentration of each 
was estimated by agrose gel electrophoresis along with molecular weight standards of a 
known concentration. Using the appropriate vector:insert ratio, set up the following reaction. 
 
Vector DNA     20-50 ng 
Insert DNA     x ng 
T4 DNA ligase    1 µl 
Ligase 10xbuffer    1 µl 
Nuclease-free water to final volume  10 µl 
 
The ligation reactions were incubated at 4°C for 16 hours. Afterwards, the ligated DNA was 
transformed into competent cells of an appropriate host strain. 
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2.7.6 Plasmid mini-preparation and maxi-preparation 
The Qiagen mini-preparation kits and maxi-preparation kits (Hilden, Germany) were used for 
the small and large scale purification of plasmid DNA respectively according to the supplier's 
instruction.  
 
2.7.7 Quantification of nucleic acids 
For the quantification of the amount of DNA and RNA, UV spectrophotometry was 
performed according to [124]. The reading at 260 nm allows calculation of the concentration 
of nucleic acid in the sample. An OD of 1 corresponds to ∼50 µg/ml for the double-stranded 
DNA, 40 µg/ml for single-stranded DNA and RNA, ∼33 µg/ml for the single-stranded 
oligonucleotides. 
The ratio between the reading at 260 nm and 280 nm (OD260:OD280) provides an estimate of 
the purity of the nucleic acid. Pure preparations of DNA and RNA have OD260:OD280 values 
of 1.8 and 2.0.  
2.7.8 Phenol-chloroform-isoamyl alcohol extraction of DNA  
Protein contaminated in DNA and RNA solutions can be effectively removed by phenol: 
chloroform: isoamyl alcohol (25:24:1) extraction. One volume of phenol: chloroform: 
isoamyl alcohol (25:24:1) was added to the samples of nucleic acid, and then vortexed 
thoroughly. The samples were centrifuged at 15000 rpm for 5 min. The aqueous phase was 
carefully removed and retained, which was then ethanol precipitated as described in 2.7.9. 
2.7.9 Ethanol precipitation of DNA 
The aqueous phase from phenol: chloroform: isoamyl alcohol (25:24:1) treatments or the PCR 
products for sequencing needing to be concentrated, were ethanol precipitated. For the 
precipitation of DNA, 0.1 volume of sodium acetate was added to the aqueous phase. Two 
volumes of absolute ethanol are added to the solution, mixed and placed at -20°C overnight to 
precipitate the nucleic acids. Precipitated nucleic acids were pelleted by centrifugation at 
13000 rpm for 20 min. Pellets were washed with 300 µl 70% ethanol by centrifugation at 
13000 rpm for 5 min. Any residual ethanol traces were removed and the pellets were air-
dried. DNA pellets were dissolved in chromatogarphy water. 
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2.7.10 DNA sequencing 
The principle of automated DNA sequencing is based on excitation and detection of 
fluorescent didesoxynucleotides which terminate DNA synthesis [125] and in parallel label 
the DNA at different locations by means of PCRs. The PRISMTM Ready Reaction 
DyeDeoxyTM Terminator Cycle Sequencing Kit (Perkin Elmer) was used for the PCR stage of 
the sequencing protocol. The PCR reactions were set up as following: 
4 µl Terminator premix 
1.0 ng DNA-sample 
3-5 pmol Oligonucleotide-primer 
ad 20 µl H2O 
 
PCR reactions were performed in a thermal cycler using a three-step-cycle for a total of 25 
cycles: 
 
20 sec 96 °C  Denaturation 
40 sec 45 °C  Primer-annealing 
20 sec 60 °C  DNA-extension 
4 min 60 °C  Last extension 
 
The amplified DNA products were purified and dried as described in 2.7.9. The DNA 
precipitates were dissolved in TSR-buffer from Applied Biosystems and denatured at 90°C 
for 2 min. The denatured DNA fragments were subject to capillary electrophoresis in a 
‘Performance Optimized Polymer’ and the results were analysed on ABI Prism 310 
Sequencer.  
 
2.8 Nuclear extraction and electrophoretic mobility shift assay (EMSA) 
Preparation of nuclear extracts and EMSAs were performed as described previously [126]. 
2.8.1 Nuclear extraction 
HepG2 cells were stimulated with 100 U/ml IL-6 or IL-1β for 20 min. For IL-1β/IL-6 co-
stimulation IL-1β was given 10 min prior to IL-6. Cells were washed twice with cold PBS 
(containing 100 µM Na3VO4) and re-suspended in 400 µl buffer A on ice for 10 min. The 
nuclei were collected after centrifugation at 13000 rpm for 10 sec and resuspended with 40 µl 
buffer C for 30 min on ice. The nuclei debris was centrifuged at 13000 rpm in a 
microcentrifuge for 10 min and supernatants containing the nuclear extracts were frozen and 
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stored at -80°C. The protein concentration of the nuclear extracts was determined with the 
BioRad reagent (Bio-Rad, München, Germany). 
 
Buffer A:     Buffer C: 
 
10 mM Hepes-KOH, pH 7.8  20 mM Hepes-KOH, pH 7.8 
1.5 mM MgCl2    1.5 mM MgCl2 
10 mM KCl    420 mM NaCl 
0.5 mM DTT    0.2 mM EDTA 
0.2 mM PMSF    25 % Glycerine 
1 mM Na3VO4   0.5 mM DTT 
      0.2 mM PMSF 
      1 mM Na3VO4 
 
2.8.2 Oligonucleotides hybridization and labeling 
For EMSA, the two single strand oligonucleotides were annealed before labeling. 10µl 100 
pmol/ml of each oligonucleotide were mixed with 1.5 µl 5M NaCl in the final volume of 50 
µl, then heated to 95° C for 10 sec. The whole reaction mixture was allowed to cool slowly in 
a thermal cycle for efficient annealing. Klenow enzyme was utilized to catalyze the 
attachment of [α-32P]dATP to the annealed fragments (3´-hydroxyl groups). 
Labelling reaction: 
 
  2.5 pmol DNA (2.5 pmol/µl) 
  6  µl 10 x Restriction buffer M (Boehringer Mannheim) 
  1  µl dCTP (0.5 mM) 
  1  µl dGTP (0.5 mM) 
  1  µl dTTP (0.5 mM) 
  45.5 µl H2O 
  2  µl [α 32P]dATP 
  2.5 µl Klenow Enzyme (5 U) 
 
 
2.8.3 Electrophoretic mobility shift assay (EMSA) 
8 µg protein was incubated with a surplus of double-stranded [32P]-labeled κB site 5’-
GATCCATGGGGAATTCCCCATG-3’) for binding NF-κB; [32P]-labeled m67SIE (5‘-
GATCCGGGAGGGATTTACGGGAAATGCTG-3’) for binding STATs; in gel shift 
incubation buffer for 20 min at RT. In supershift experiments, 2 µg antibodies were added to 
nuclear extract and incubated at 4°C for 20 min before addition of the reaction mixture and 
the labeled probe. The protein/DNA complexes were separated on a 4.5% polyacrylamide gel 
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containing 7.5% glycerol in 0.25-fold TBE at 20 V/cm for 4 h. Gels were fixed in 10% 
methanol, 10% acetic acid, and 80% water for 1 h, dried, and autoradiographed. 
 
5 × DNA binding buffer: 
 
 50 mM  Hepes-KOH, pH 7.8 
   5  mM  EDTA 
 25 mM  MgCl2 
 50 % V/V  Glycerine 
 
 
Reaction mixture for one sample (the final volume 20 µl): 
 
 8 µg Nuclear extract 
 4 µl 5 × DNA binding-buffer 
     0.1 µl 1M DTT 
     0.2 µl 200 mM PMSF 
 1 µl Poly(dI-dC)-Poly(dI-dC) (Stock concentration: 1 mg/ml)  
 2 µl BSA (Stock concentration: 10 mg/ml) 
ad   20 µl H2O 
 
 
Gel preparation: 
 
     6.75 ml Acrylamide mix (40%) 
     5.25 ml Glycerine 86 % 
     3 ml 5 × TBE 
     45 ml H2O 
     400 µl 10 % APS 
     40 µl TEMED 
 
 
Running buffer:  
     0.25 × TBE 
2.9 Reporter gene assay 
Genetic reporter systems have contributed greatly to the study of eukaryotic gene expression 
and regulation. Although reporter genes have played a significant role in numerous 
applications, both in vitro and in vivo, they are most frequently used as indicators of 
transcriptional activity in cells. Briefly, an exogenous reporter gene (such as luciferase) is 
fused to a promoter sequence (SOCS3 promoter used in this study) in an expression vector 
that is transferred into cells. Following transfer, the cells are assayed for the presence of the 
reporter by directly measuring the enzymatic activity of the reporter protein. To normalize the 
transfection efficiency, another control vector (pCH110, Phamarcia) expressing β-
galactosidase was co-transfected. 
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2.9.1 Transient transfection 
For transfection of HepG2 cells, cells were grown on 6 cm plates to 30% confluency and 
transfected in DMEM supplemented with 10% FCS. Calcium phosphate precipitation was 
performed with 3 µg reporter construct, 2 µg β-galactosidase expression vector (pCR3lacZ; 
Amersham Biosciences (Uppsala, Sweden)). Transfections were adjusted with control vectors 
to equal amounts of DNA. Cells were incubated with the precipitate for 16 h, washed twice 
with PBS, and let for additional 8-10 h in fresh medium. For kinetic studies high efficient 
gene transfer was performed with Fugene 6 reagent (Roche Biotechnology, Mannheim, 
Germany) according to the manufacturer’s instructions.  
2.9.2 Luciferase-assay 
Cells were washed twice with cold PBS and lysed with 240 µl of 1×reporter lysis buffer. Cell 
extracts were collected after centrifugation at 13000 rpm for 2 min. 20 µl of the cell extract 
was loaded into each well of a 96-well microplate. Then 80 µl of luciferase assay reagent 
(Promega, Madison, WI) was added, and luciferase activity was immediately measured in a 
luminometer (EG&G Berthold, Bad Wildbad), which was programmed to read for 10 sec. 
Transfection efficiency was always normalized by measuring β-galactosidase activity. Assays 
were carried out in triplicate and the experiments were repeated at least three times. 
2.9.3 β-Galactosidase-assay 
The transfection efficiency was monitored by co-transfected the control reporter plasmid pCH 
110 (Pharmacia). To measure the β-Galactosidase activity, 100 µl cell lysate was incubated 
with 500 µl β-Galactosidase-buffer and 100 µl ONPG (1 mg/ml o-Nitrophenylgalactosid), a 
substrat of β-Galactosidase, at 37 °C. When the solution becomes yellow, the reaction was 
stopped by adding 250 µl 1M Na2CO3 and the absorption of the samples was measured at OD 
420 nm. The β-Galactosidase activity was calculated as following: 
Activity = (OD420 x 6000)/ (Incubation time in min) 
 
β-Galactosidase buffer: 
 
 60  mM Na2HPO4 
 40  mM NaH2PO4 
 1   mM KCl 
 1   mM MgCl2 
 + 386 µl β-Mercaptoethanol per 100 ml solution 
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2.10 Preparation of cell lysates for immunoprecipitation 
HepG2 cells were grown on 10 cm plate to 80% confluent and stimulated with or without 
cytokine as indicated in the figure legends. Cells were washed twice with cold PBS 
(containing 1 mM Na3VO4) and then lysed in 500 µl RIPA buffer which contains freshly 
supplemented protease inhibitors on ice for 30 min. The lysates were centrifuged at 13000 
rpm for 5 min to remove nuclei. The supernatants were transferred to the fresh microfuge 
tubes. Before adding antibodies protein amounts were adjusted to be equal.  
 
RIPA-lysis buffer: 
 
50  mM  Tris/HCl, pH 7.5  
150  mM  NaCl 
0.5 %  NP-40 
15  %  glycerol  
10  µg/ml Leupeptin 
10  µg/ml Aprotinin 
10  µg/ml Pepstatin 
1   mM NaF  
1   mM  Na3VO4 
  
2.11 Determination of protein concentration according to Bradford 
Protein content determination was performed with Bio-Rad (München) as previously 
described by Bradford [127]. The Bio-Rad protein assay is based on the differential colour 
change of a dye in response to various concentrations of protein. To create the standard curve, 
0-12 µg BSA was dissolved in 800 µl water and 200 µl 5× Bio-Rad reagent and incubated at 
RT for 5 min. The OD595 was plotted versus concentration of standards. For each sample, 3 µl 
lysates were added to 1 ml 1×Bio-Rad and the absorption of OD595 was measured. The 
concentration (µg/µl) of the sample is the value of OD595 multiplied with factor 5.44. 
2.12 Biotinylation of antibodies 
The SOCS3-M20 antibodies were biotinylated as described by Pierce (Rockford, IL). Briefly, 
25 µl SOCS-3 M-20 (Santa Cruz) was incubated with 20 µl H2O, 5 µl 1 M NaHCO3, and 
3.3µg long chain biotin at RT for 2 h. To remove un-reacted biotin, the labelled antibodies 
were dialysed against 500 ml PBS extensively at 4°C overnight. After dialysis, antibody 
solution was transferred to a new microfuge tube and stored at 4°C for use. 
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2.13 Immunoprecipitations 
Immunoprecipitations were carried out essentially as described previously by Harlow and 
Lane[128]. 3 µl rabbit polyclonal anti-SOCS-3 antibodies (kind gift from Dr. J. A. Johnston) 
were added to the same amount of protein lysates. Meanwhile, Protein A-Sepharose was 
dissolved in RIPA-lysis buffer at the concentration of 5 mg/100 µl and incubated for at least 1 
h at 4°C. The antibody-antigen-complexes were incubated overnight at 4°C. Afterwards, 100 
µl Protein A-Sepharose was added to the immune complexes and incubated at 4°C with 
rocking for 1 h. The beads were collected by centrifugation at 13000 rpm for 1 min at 4°C and 
washed twice with RIPA-wash buffer. The final wash was removed as completely as possible 
and the pellets were re-suspended in 20 µl Laemmli-loading buffer. The immune complexes 
were boiled to 95°C for 5 min and centrifuged at 13000 rpm for 1 min. The supernatants were 
loaded onto the gel. 
RIPA-wash buffer:  
50  mM  Tris/HCl, pH 7.5 
100  mM  NaCl 
0.5 %  NP-40 
15 %  glycerol 
   1 mM EDTA 
2.14 SDS-polyacrylamide gel electrophoresis 
SDS-PAGE, first described by Laemmli [129], separate proteins by molecular weight under 
denaturing conditions. Interaction of SDS with the amino acid chain of the protein results in a 
net negative charge, and therefore proteins are separated according to the length of the protein 
i.e. molecular weight.   
Acrylamide mix:  30 % Acrylamide 
                  0.8 % Bisacrylamide 
Separating gel:   
7.34 ml Millipore water 
               3.36 ml Acrylamide mix 
                      3.8 ml 1.5 M Tris/HCl pH 8.8 
    75 µl 10 % SDS 
    15 µl TEMED 
    75 µl 20 % APS 
 
Stacking gel:   4 ml Millipore water 
    0.6 ml Acrylamide mix 
    313 µl 2 M Tris/HCl pH 6.8 
    25  µl 10 % SDS 
    5 µl TEMED 
    40 µl 20 % APS 
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Running buffer:      25 mM Tris base 
    192 mM Glycine 
             0.1 % SDS 
 
The electrophoresis was carried out for 16 h at constant current of 4 V or 1.5 h at the constant 
current of 35 mA. 
2.15 Semi-dry electrophoretic transfer   
Transfer of proteins from a gel to PVDF membrane was performed as described [128]. An 
appropriate sized PVDF membrane pre-soaked in 100% methanol for 5-7 sec and then in 
distilled water for 5 min, was placed in anode buffer II for 15 min. The gel was soaked in 
cathode buffer for 5 min. On the bottom of the apparatus, the gel, PVDF membrane and 
wetted paper were assembled in the following order:  
 
1. Bottom electrode 
2. 6 layers absorbent Whatman paper soaked in anode buffer I 
3. 3 layers absorbent Whatman paper soaked in anode buffer II 
4. PVDF-Membrane soaked in anode buffer II 
5. Polyacrylamide gel wetted with cathode buffer 
6. 6 layers absorbent Whatman paper soaked in cathode buffer 
7. Top electrode 
 
Any air bubbles were removed by rolling a pipet over the gel-paper sandwich. The 
sandwiched gel was placed into the transfer tank and electroblotting was carried out at the 
current of 0.8mA/cm2 for 1 h. 
 
Anode buffer-I: 
0.3 M Tris base 
20  % Methanol 
 
Anode buffer-II: 
0.025 M Tris base 
20  % Methanol 
 
Cathode buffer: 
0.4 M 6-Aminohexanoic acid 
20 % Methanol 
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2.16 Immunblotting 
After electroblotting, the PVDF membranes were blocked with 10 % BSA in TBS-N for 30 
min. The membranes were washed three times with TBS-N for 5 min each, and probed with 
the primary antibody (1:1000) for 1 h at RT with agitation.  The blots were washed three 
times with TBS-N for 5 min each then the HRP-conjugated second antibody was added for 
1 h at RT with agitation. The membranes were developed with an enhanced 
chemiluminescence kit Amersham Biosciences (Uppsala, Sweden). 
 
TBS-N buffer: 
 
2.42 g/l Tris base 
8  g/l NaCl 
3.81 ml/l 1 M HCl, pH 7.6  
0.1 %v/v NP-40 
2.17 Chromatin immunoprecipitation (ChIP) 
2.17.1 Shearing of genomic DNA by sonication 
HepG2 cells were grown to 80% confluence and serum-starved for 24 hours. Where 
indicated, cells were treated with 100 U/ml IL-6 or IL-1β for 20 min. For IL-1β/IL-6 co-
stimulation IL-1β was given 10 min prior to IL-6. After stimulation cells were fixed by 
adding formaldehyde to a final concentration of 1% at room temperature for 10 min. Cells 
were washed three times with ice-cold PBS for 10 min, centrifuged, re-suspended in L1 buffer 
supplemented with protease inhibitors for 5 min. Nuclei were centrifuged at 3000 rpm and re-
suspended in L2 buffer. Chromatin was sheared by sonification (4x16 s at about 50% output, 
Branson Sonifier). Debris was eliminated by centrifugation and the supernatant diluted (1:10) 
in dilution buffer.  
 
L1 buffer:      L2 buffer: 
 
50  mM  Tris/HCl, pH 8.0   50  mM  Tris/HCl, pH 8.0 
2 mM EDTA     1 %  SDS 
0.1 %  NP-40      5  mM  EDTA 
10 %  glycerol 
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Dilution buffer:  
 
50  mM  Tris/HCl, pH 8.0 
0.5 %  NP-40 
0.2  M  NaCl 
5  mM  EDTA 
 
2.17.2 Immunoprecipitation  
Immunoprecipitation was performed with specific antibodies overnight. 20 µl Protein A–
Sepharose (Amersham Pharmacia Biotec) was added at 4 °C for 45 min. Immune complexes 
were washed three times for 5 min with high-salt buffer. Complexes were washed three times 
in 1x TE and finally extracted in 1x TE containing 2% SDS.  
2.17.3 Reverse cross link and DNA extraction  
Cross linking of the protein with DNA was reverted by heating at 65 °C overnight. 
Supernatants were then incubated with proteinase K (100 µg at 50 °C for 2 h). DNA was 
extracted with phenol-chloroform and precipitated in ethanol as described in 2.7.8 and 2.7.9. 
The precipitated DNA was dissolved in 50 µl TE.  
2.17.4 PCR and visualization of the bands in the gel  
2.5 µl DNA was used for PCR, with specific primer for the human IκBα or SOCS3 promoter. 
The following promoter-specific primers were used: 5’-GACGACCCCAATTCAAATCG-3’ 
and 5’-TCAGGCTCGGGGAATTTCC-3’ for IκBα promoter and 5’-
GCTCAGCCTTTCTCTGC-3’ and 5’-CGAAGCGGCAGCAGC-3’ for the -131 to +32 
region of the human SOCS3 promoter and 5’-CAGGGTTGGCAAAGAAC-3’ and 5’-
ACCTGGAGAGCCTC-3’ for the -722 to -420 region of the human SOCS3 promoter 
(numbering relative to the proposed transcription starting site).  
 
The PCR reaction was performed for 35 cycles in total volume of 25 µl (1.25 U Taq DNA 
polymerase; 100 ng of each primer; 200 µM dNTP; 2.5µl of 10x Taq buffer). PCR conditions 
were as follows: the first denaturation was 94 °C for 180 s then 35 cycles consisting of 
denaturation ( 94 °C for 45 s), annealing (60 °C for 60 s),  and elongation (72 °C for 60 s); the 
final elongation was carried out at 72 °C for 10 min. DNA-fragments were separated by 
electrophoresis in a 2 % agarose gel. DNA was visualized with ethidium bromide. 
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High-salt buffer: 
 
  20  mM  Tris/HCl, pH 8.0 
  0.1 %  SDS 
  1 %  NP-40  
  2  mM  EDTA  
0.5  M  NaCl 
2.18 mRNA extractions  
Total RNA from 5x106 cells was isolated with the total RNA kit from Qiagen (Hilden, 
Germany) as described in the manufacturer’s instructions. 
2.19 Northern blotting 
10 µg RNA was mixed with denaturing buffer (20 mM MOPS, 1 mM EDTA, 2.2 M 
formaldehyde, 50% formamide, bromphenol blue, 4mM Na-acetate, pH 7.0) and denatured at 
66° C for 5 min. RNA was subjected to electrophoresis on a 1 % agarose gel containing 0.2 M 
formaldehyde, 20 mM MOPS, 1 mM EDTA, 5 mM Na-acetate, pH 7.0. The RNA was blotted 
by capillary blot method to NitroPlus transfer membrane (Micron Separations, Westboro, 
MA). RNA was immobilized at 80 °C for 2 h. The membranes were blocked in  pre-
hybridization buffer at 66 °C for at least 2 h. Hybridisation was performed at 66 °C with 
labeled cDNAs overnight. The Xba1/Mlu1 fragment of pEF-FLAG-I/mSOCS3 (kindly 
provided by D. Hilton, Melbourne, Australia) was labeled with the random primed DNA 
labeling kit (Roche Molecular Biochemicals, Mannheim, Germany). The membranes were 
washed twice in 2 x NaCl/citrate buffer, 0.2 % SDS at room temperature for 20 min. 
Afterward washing was performed in 0.2 x NaCl/citrate buffer, 0.2 % SDS at 66° C for 20 
min. The membranes were dried and subjected to auto radiography using intensifying screen 
at –80° C. For counterstaining membranes were blocked and re-probed with an EcoR1/Xho1 
DNA fragment of the GAPDH-cDNA. 
 
 Pre-hybridization buffer:   Wash buffer 1:  Wash buffer 2: 
 
 1 M NaCl     2 x SSC buffer  0.2 x SSC buffer 
 10 % dextran sulfate   0.2 % SDS  0.2 % SDS  
 1 % SDS 
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2.20 cDNA synthesis 
1 µg of total RNA was primed with random hexamers, and cDNA was synthesized from 
mRNA by 1st Strand cDNA Synthesis Kit for RT-PCR (AMV) from Roche (Mannheim, 
Germany) according to the manufacturer's description.  
2.21 Quantification-PCR (Taqman PCR) 
2.21.1 Taqman PCR 
cDNA was amplified and quantified using SYBR Green PCR reagents from PE Applied 
Biosystems (Darmstadt, Germany). Briefly, the cDNAs for SOCS3 and internal control β-
actin were amplified using specific primers for β-actin (forward primer:  5'-
CCCTGAGGCTCTTTTCCAG-3' and reverse primer: 5'-TGCCACAGGATTCCATACCC-
3') or for SOCS3 (forward primer: 5'-CACCTGGACTCCTATGAGAAAGTGA-3' and 
reverse primer: 5'-GGAGCATCATACTGATCCAGGAA-3'). The PCR reaction was 
performed in a final volume of 25 µl containing 2.5 µl cDNA, 100 nM of each primer, 12.5 µl 
SYBR Green PCR buffer (PE Applied Biosystems, Darmstadt, Germany) with ABI 7000 
instrument. After denaturing for 15 min at 94°C, amplification was performed by 40 cycles of 
15 sec at 94°C, and a combined annealing/extension step of 60 sec at 60°C using the ABI 
prism 7000 (PE Applied Biosystems, Darmstadt, Germany).  
2.21.2 Quantification of target gene expression 
For quantification of gene expression the comparative method recommended for the ABI 
PRISM 7700 Sequence Detection System (PE Applied Biosystems, Darmstadt, Germany) was 
used. Initially, a validation experiment was performed which demonstrated equal transcription 
efficiencies for target and reference genes. 
 
The PCR cycle number “CT” was determined at which an increase in SYBR Green 
fluorescence above the baseline signal can first be detected. “)CT” was calculated by 
subtracting the cycle number “CT” obtained for β-actin (reference gene) from the cycle 
number “CT” for SOCS3 (target gene). Triplicate “)CT” values were averaged for each 
animal. The fold induction of SOCS3 mRNA at each time point was calculated as follows: 
first, the averaged )CT of three untreated wild-type mice was substracted from the averaged 
)CT of three to four identically treated animals at each time point to get the ))CT, then the 
“2-())CT) formula” was applied.   
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3 Results 
3.1 Dual function of IL-1β on IL-6-induced SOCS3 expression 
3.1.1 IL-1β counteracts IL-6-dependent SOCS3-promoter activation 
Previous experiments suggested that SOCS3 may be negatively regulated by IL-1β in a 
similar way as α2-macroglobulin (α2M) and fibrinogen [7, 8]. To analyze the regulation of 
IL-6-mediated SOCS3 induction by IL-1β, reporter gene assays were performed with a 
SOCS3 promoter luciferase construct in human HepG2 hepatoma cells. Figure 3.1.1 (left part) 
shows that the SOCS3 promoter was responsive to stimulation with IL-6 (2nd bar). It has been 
reported previously that IL-1β induces SOCS3 expression in primary rat hepatocytes and 
adipocytes [130, 131]. In contrast, SOCS3 promoter activity was hardly affected by IL-1β (3rd 
bar) in HepG2 cells. However, IL-1β counteracted IL-6-dependent promoter activation since 
co-incubation with IL-1β significantly reduced IL-6-induced reporter gene activity (compare 
bars 2 and 4), which is consistent with the previous report from our laboratory [7].  
 
Figure 3.1.1: Inhibition of an IL-6-induced SOCS3-promoter reporter by IL-1β. 
HepG2 cells were co-transfected with a reporter gene construct containing the SOCS3-promoter fused to the 
firefly luciferase gene and a control plasmid (left part) or an expression vector for the non-degradable IκBα 
mutant (right part). An expression vector for β-galactosidase was co-transfected for monitoring transfection 
efficiency. After transfection, cells were stimulated with 100 U/ml of IL-1β or IL-6 (100 U/ml) or both for 16 h. 
Luciferase activity in cellular extracts of these cells was determined and normalized to β-galactosidase activity, 
as outlined in Materials and Methods. 
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To clarify whether the inhibitory effect of IL-1β on SOCS3 promoter activity is mediated via 
NF-κB pathway, a non-degradable IκBα(S/A) inhibitor was transiently transfected into 
HepG2 cells to prevent NF-κB activation. As indicated in the right part of figure 3.1.1, 
transient expression of IκBα(S/A) blocked the activity of IL-1β to inhibit SOCS3-promoter 
driven reporter expression. 
3.1.2 Stable expression of a non-degradable IκB(S/A) mutant prevents IL-1β to inhibit 
IL-6-induced SOCS3 promoter activity 
In order to investigate the contribution of NF-κB in the cross-talk between IL-1β and IL-6, 
HepG2 cells were engineered by retroviral gene transfer for stable expression of the 
IκBα(S/A) mutant form that could not be phosphorylated and subsequently degraded after 
stimuli. Therefore, NF-κB should be persistently sequestered by this mutant in the cytosol. As 
a control, HepG2 cells were infected with a virus lacking the IκBα(S/A)-cDNA (HepG2-
mock). To confirm that NF-κB activation was functionally blocked in these cells, the 
degradation of IκB was investigated by Western blotting. Figure 3.1.2A shows that 
degradation of endogenous IκBα occurred 2 min after IL-1β treatment of HepG2-mock cells. 
IL-1β-induced IκBα re-expression was detectable after 20 min and further increased by 40 
min (figure 3.1.2A, left panel). In contrast, expression of the endogenous IκBα as well as of 
the exogenous IκBα(S/A) mutant was unaffected by IL-1β treatment in HepG2-IκBα(S/A) 
cells (right panel). In parallel, DNA binding activity of NF-κB was determined by EMSA 
with the κB-site-containing DNA-probe after IL-1β stimulation. In accordance with the 
kinetics of degradation of IκB, IL-1β-induced NF-κB binding to the κB-site in HepG2-mock 
cells was detectable already after 1 min and further increased during the following 40 min 
(figure 3.1.2B, left panel). In contrast, no NF-κB binding in response to IL-1β was found in 
HepG2-IκBα(S/A) cells (right panel). Taken together, these data demonstrate that in HepG2 
cells which stably express a non-degradable IκBα mutant, IκBα(S/A), NF-κB activation is 
blocked.  
 
To further confirm the effect of NF-κB on IL-1β-mediated regulation of SOCS3 promoter 
activity, reporter gene assays were also carried out in the stably transfected HepG2 IκBα(S/A) 
cells. Similar as in figure 3.1.1 IL-1β counteracted IL-6-induced SOCS3-reporter expression, 
whereas IL-1β alone had no effect on the reporter in the control cells (Fig. 3.1.2C, left panel). 
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In contrast, IL-6-dependent luciferase activity was hardly affected by IL-1β in cells 
expressing the non-degradable IκBα(S/A) inhibitor (figure 3.1.2C right panel, compare bars 2 
and 4). Taken together, these data suggest that IL-1β acts negatively on IL-6-mediated 
SOCS3 promoter activation through an NF-κB-dependent mechanism. 
Figure 3.1.2: Loss of NF-κB activation prevents the inhibitory effect of IL-1β on IL-6-induced SOCS3 
expression. 
(A) HepG2-mock (left panel) and HepG2-IκBα(S/A) cells (right panel) were stimulated with 100 U/ml IL-1β for 
the times indicated. Cellular extracts were prepared and the same amounts of proteins subjected to SDS/PAGE. 
Expression of endogenous IκBα and exogenous IκBα(S/A) was monitored by Western blotting with an antibody 
specific for IκBα. (B) HepG2-mock (left panel) and HepG2-IκBα(S/A) cells (right panel) were stimulated with 
100 U/ml IL-1β for the times indicated. Nuclear extracts were prepared and same amounts of proteins subjected 
to EMSA with the κB-site-containing DNA fragment. (C) HepG2-mock (left panel) and HepG2-IκBα(S/A) cells 
(right panel) were transfected with a reporter gene construct containing the SOCS3-promoter fused to the firefly 
luciferase gene. An expression vector for β-galactosidase was co-transfected for monitoring transfection 
efficiency. After transfection, cells were stimulated with 100 U/ml IL-1β or IL-6 (100 U/ml) or both for 16 h. 
Luciferase activity in cellular extracts of these cells was determined and normalized to β-galactosidase activity, 
as outlined in Materials and Methods.  
Results 
 
 37
3.1.3 IL-1β inhibits IL-6-induced STAT3 phosphorylation and DNA binding activity 
independent on NF-κB activation 
Although it has been well documented that IL-1β inhibits the expression of numerous IL-6-
induced type II acute phase genes , it remained controversial whether overall activation of 
STAT3 is affected by IL-1β [7, 115, 132]. To clarify this issue, IL-6-induced STAT3 
phosphorylation and DNA binding activity were determined in the presence or absence of IL-
1β. As shown in figure 3.1.3A, exposure of HepG2 cells to IL-6 for 20 min resulted in 
substantial STAT3 activation. In contrast, no protein complexes binding to the labelled SIE 
probe were detectable after 20 min IL-1β treatment. However, the DNA binding activity of 
STAT3 was markedly inhibited by a 10 min IL-1β pretreatment (lane 2 compared with lane 4). 
The capacity of IL-1β to inhibit IL-6-induced STAT3 binding to its regulatory site could be 
due to the down-regulation of tyrosine phosphorylation. To examine this possibility, Western 
blotting analysis was performed with anti-(phosphotyrosine-STAT3) antibodies and anti-
STAT3 antibodies. As shown in figure 3.1.3B (lane 2), treatment with IL-6 induced 
significant STAT3 tyrosine phosphorylation in HepG2 cells. STAT3 tyrosine phosphorylation 
was markedly suppressed by pretreatment with IL-1β for 10 min (figure 3.1.3B, compare lane 
2 and lane 4). STAT3 levels did not change after IL-1β treatment (figure 3.1.3B, bottom 
panel), indicating that the decrease in STAT3 DNA binding activity was not due to decreased 
protein levels. 
 
Whether NF-κB is required for the ability of IL-1β to inhibit the IL-6-induced STAT3 
activation remained unclear. Therefore, the possible role of NF-κB in mediating the inhibition 
of IL-1β on IL-6-induced STAT3 activation was determined in HepG2 IκB(S/A) mutant cells. 
Similar as in the HepG2 cells, the inhibition of STAT3 DNA binding activity and tyrosine 
phosphorylation by IL-1β occurred not only in mock but also in HepG2 IκB(S/A) cells. Taken 
together, these results demonstrate that IL-1β rapidly inhibits IL-6-induced STAT3 tyrosine 
phosphorylation and DNA binding activity independent of the activation of NF-κB. 
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Figure 3.1.3: IL-1β counteracts STAT3-activation independent of NF-κB activation. 
Control HepG2 cells, HepG2 cells expressing the IκBα (S/A) mutant and HepG2 cells infected with the virus 
lacking IκBα(S/A)-cDNA were stimulated with IL-6 (100 U/ml), IL-1 (100 U/ml) or both cytokines for 20 min. 
For IL-1β/IL-6 co-stimulation IL-1β was given 10 min prior to IL-6. (A) EMSA: nuclear extracts were prepared 
and tested for DNA binding to an optimized STAT3 binding site of the c-fos promoter. (B) Western blotting:  
Whole cell lysates were prepared, and proteins subjected to SDS-PAGE and activation of STAT3 was analyzed 
with antibodies specific for phosphotyrosine 705 of STAT3 (upper panel). As loading control, the membrane 
was stripped and re-probed with antibodies specific for STAT3 (lower panel). 
 
3.1.4 The inhibitory activity of IL-1β on SOCS3-promoter activation is time-dependent 
SOCS3 is an immediate early IL-6 response gene. Therefore, the kinetics of IL-1β-induced 
inhibition of the SOCS3-reporter was analyzed in the initial phase of expression. SOCS3-
promoter driven reporter gene expression was assessed 50, 80, 180 and 240 min after 
stimulation of HepG2 cells with IL-6. Reporter gene activity increased within the first 3 hours 
but did not rise further up to 4 hours of IL-6 stimulation. Gene induction was most efficiently 
suppressed by IL-1β in cells stimulated for more than 3 hours with IL-6 (figure 3.1.4A, panels 
3 and 4), whereas cells stimulated for 80 min were less sensitive to IL-1β (figure 3.1.4A, 
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panel 2). Strikingly, a reproducible slight increase of reporter gene induction was observed in 
cells stimulated with IL-6 for only 50 min (figure 3.1.4A, panel 1).  
To confirm the significance of the IL-1β-dependent increase in SOCS3-promoter activation in 
the initial phase of IL-6 stimulation shown in figure 3.1.4A (panel 1), the duration of IL-1β 
pre-stimulation was extended up to 40 min prior to addition of IL-6 (figure 3.1.4B). 
Stimulation of HepG2 cells with IL-6 for 50 min led to a 2-fold induction of reporter gene 
expression (left panel). As described in figure 3.1.4A, a modest but significant (p=0.007) 
increase of reporter gene expression was detected when IL-1β treatment started 10 min prior 
to IL-6 stimulation (2nd panel). This increase was further magnified when the preincubation 
time of IL-1β was further extended (panels 3-5). These data suggest that IL-1β acts negatively 
on SOCS3 promoter activation only in response to long term IL-6 stimulation. In the early 
phase upon IL-6 stimulation, however, a positive regulatory function of IL-1β on IL-6-
induced SOCS3 promoter activation was observed. 
Additionally, an identical time-course reporter gene assay was performed in HepG2 cells 
expressing the IκBα mutant (figure 3.1.4C). In these cells, the effect of IL-1β on IL-6-
induced reporter gene expression was observed neither during the initial phase nor during the 
latter phase. Taken together, these data suggest IL-1β to regulate IL-6-induced SOCS3-
promoter activation dually in a time-dependent manner. Moreover, NF-κB is critical for the 
observed dual regulatory effect of IL-1β.  
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Figure 3.1.4: Time-dependent activation/inhibition of the IL-6-induced SOCS3-promoter activation by IL- 
1β. 
HepG2 cells were transfected with the SOCS3 reporter construct and β-galactosidase expression vectors and 
reporter gene assays were performed as described for figure 3.1.1. (A) To focus on the initial phase of SOCS3-
reporter gene expression the stimulation times were reduced to 50 min, 80 min 180 min or 240 min (instead of 
16 h, described in the previous figures). Where indicated, IL-1β was given 10 min prior to addition of IL-6 to the 
medium. (B) Pre-stimulation with IL-1β was extended up to 40 min prior to stimulation with IL-6 for 50 min. 
(C) The analogous experiment as described in figure 3.1.4A was performed with HepG2-IκB(S/A) cells. 
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3.1.5 IL-1β mediates enhanced SOCS3 expression in response to IL-6 
It was of interest to know whether the supporting activity of IL-1β on IL-6-induced SOCS3 
promoter activation also affects the levels of SOCS3 mRNA and SOCS3 protein in the initial 
phase of IL-6 stimulation. Intentionally, in the following experiments only the initial phase of 
SOCS3 induction has been assessed in order to exclude putative feedback inhibitory effects 
mediated by SOCS3 itself.  
 
First, SOCS3 mRNA was isolated from HepG2 cells stimulated for up to 70 min with IL-6 in 
the presence or absence of IL-1β and analyzed by Northern blotting (figure 3.1.5A). Upon 
treatment with IL-6 alone SOCS3 mRNA was detectable at 30 min, peaked at 45 min and 
diminished by 70 min (left part). In cells treated with both IL-6 and IL-1β, SOCS3 mRNA 
levels were significantly higher and already detectable 15 min post stimulation.  
 
In parallel, SOCS3 protein expression was determined by immunoprecipitation and 
subsequent Western blotting immediately after stimulation with IL-6 (figure 3.1.5B, C). 
SOCS3 protein was detectable after IL-6 stimulation for 40 min and further increased during 
the following 20 min. Consistent with the mRNA data, IL-1β treatment resulted in enhanced 
SOCS3-protein expression (compare lanes 6 and 7 or 8 and 9 in figure 3.1.5B). Moreover, 
figure 3.1.5C shows an IL-1β dose-dependent increase of SOCS3 expression in the early stage 
of IL-6-induced SOCS3 expression. From these data we concluded that IL-1β enhances time 
and dose-dependently IL-6-induced endogenous SOCS3 expression. 
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Figure 3.1.5: Enhanced SOCS3 expression by IL-1β.  
(A-C) Induction of IL-6-dependent expression of endogenous SOCS3 mRNA (A) and SOCS3 protein (B, C) was 
analyzed in presence or absence of IL-1β in HepG2 cells. To exclude putative secondary effects mediated by 
SOCS3 itself only the initial phase of SOCS3 induction was studied in these experiments. (A) Kinetics of SOCS3 
mRNA expression. HepG2 cells were stimulated with 100 U/ml IL-6 for 15-to 70 min (left part). For co-
stimulation, IL-1β (100 U/ml) was given 10 min prior to IL-6 (right part). Total mRNA was isolated and analyzed 
by Northern blotting with a specific probe for SOCS3 (upper panel). For loading controls, the membrane was re-
probed with a GAPDH-specific probe (lower panel). (B) Kinetics of SOCS3 protein induction. Cells were treated 
with 100 U/ml IL-6 or IL-1β for the times indicated. For IL-1β/IL-6 co-stimulation IL-1β was given 10 min prior 
to IL-6. Cellular extracts were prepared and lysates were incubated with antibodies against SOCS3 (IP: SOCS3). 
Protein/antibody complexes were separated by SDS-PAGE and analyzed by Western blotting with the second 
type of SOCS3 antibodies (Santa Cruz Biotechnology) which were biotinylated before usage (IB: SOCS3). 
Staining of SOCS3 protein was performed with streptavidin-coupled HRP. (C) Dose-dependent effect of IL-1β on 
IL-6-induced SOCS3 expression. HepG2 cells were stimulated with IL-6 (100 U/ml) for 60 min. IL-1β (0, 100, 
400 or 800 U/ml) was given 10 min prior to IL-6. SOCS3 protein was measured as described above. 
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3.1.6 NF-κB is crucial for the enhancing effect of IL-1β on IL-6-dependent induction of 
SOCS3 mRNA and protein 
To clarify whether NF-κB is crucial for IL-1β-dependent enhancement of IL-6-induced 
SOCS3 expression, the amount of endogenous SOCS3 protein was measured by means of 
immunoprecipitation in HepG2-IκBα(S/A) cells (figure 3.1.6A). Consistent with the previous 
experiments (figures 3.1.5) pretreatment with IL-1β resulted in augmented IL-6-induced 
SOCS3 expression in HepG2 cells. Surprisingly, in cells expressing IκBα(S/A) IL-1β was not 
simply ineffective to enhance IL-6-dependent SOCS3 expression but rather reduced SOCS3 
protein amounts (compare lanes 6 and 8 in both panels). This finding was not due to an effect 
of the retroviral gene transfer since cells infected with control virus behaved similar as wild-
type cells (right panel of figure 3.1.6A). 
 
These observations were confirmed by analyzing SOCS3 mRNA expression in cells stably 
expressing the IκBα(S/A) inhibitor (figure 3.1.6B). SOCS3 mRNA was induced after addition 
of IL-6 for 30 min (lane 5). After 60 min of IL-6 stimulation SOCS3 mRNA levels further 
increased (lane 6). Similar as the protein expression, the levels of SOCS3 mRNA were 
suppressed by IL-1β in cells expressing the IκBα(S/A) inhibitor. Notably, IL-1β alone failed 
to induce any detectable SOCS3 mRNA and protein in agreement with the data obtained from 
reporter gene assays suggesting that IL-1β alone can not induce SOCS3 expression in 
hepatocytes. These data reflect that SOCS3 expression is positively regulated by IL-1β 
through an NF-κB-dependent mechanism and interestingly, NF-κB can act as a molecular 
switch for the effect of IL-1β because in the absence of NF-κB activation IL-1β is able to 
negatively regulate SOCS3 expression. 
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Figure 3.1.6: Crucial role of NF-κB for the enhancing effect of IL-1β on IL-6-induced SOCS3 expression. 
(A)Induction of IL-6-dependent expression of endogenous SOCS3 protein was analyzed in the presence or 
absence of IL-1β in HepG2 cells (left panel, lanes 1-4) and HepG2 cells expressing the IκBα(S/A) inhibitor 
(right panel, lanes 5-8). Cells were stimulated with IL-6 (100 U/ml), IL-1β (100 U/ml) or both for 60 min. For 
IL-1β/IL-6 co-stimulation IL-1β was given 10 min prior to IL-6. SOCS3 protein was measured by 
immunoprecipitation and subsequent Western blotting as described in the legend to figure 3.1.5. The right and 
left panels differ only in the control cells used: naïve HepG2 cells were used in the right panel, HepG2 cell 
infected with the retroviral vector lacking the IκBα(S/A)-cDNA were used in the left panel. (B) Kinetics of 
SOCS3 mRNA expression in HepG2 cells expressing the IκBα(S/A) inhibitor. HepG2 cells expressing 
IκBα(S/A) were stimulated with IL-6 (100 U/ml), IL-1 (100 U/ml) or both for 30, 60 or 120 min. For IL-1β/IL-6 
co-stimulation IL-1β was given 10 min prior to IL-6. Total mRNA was isolated and analyzed by Northern 
blotting with a specific probe for SOCS3 (upper panel). For loading controls, the membrane was re-stained with 
a GAPDH-specific probe (lower panel). 
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3.1.7 IL-1β-induced serine phosphorylation of STAT1 does not depend on NF-κB 
activation and thus is not crucial for the enhancing effect of IL-1β on IL-6-
induced SOCS3 expression 
Recently, Stark and colleagues described an IL-1β-induced STAT1 serine phosphorylation 
which in turn leads to enhanced transcriptional activity of STAT1 [133]. Therefore, we tested 
whether IL-1β stimulation leads to an enhanced SOCS3 expression through STAT1-serine 
phosphorylation. Figure 3.1.7A shows an IL-1β-dependent STAT1-serine 727 
phosphorylation in HepG2 cells (left panel, lane 3). However, tyrosine 701 phosphorylation 
of STAT1 is not observed upon IL-1β treatment (right panel, lane 3). Conversely, IL-6 
induced STAT1-tyrosine phosphorylation (right panel, lane 2) but no serine phosphorylation 
(left panel, lane 2). It has been shown  that NF-κB-activation is crucial for the enhancing 
effect of IL-1β on SOCS3 expression in figure 3.1.6. To investigate whether STAT1 serine-
phosphorylation is involved in the enhancing effect of  IL-1β on SOCS3 expression, STAT1-
serine phosphorylation was determined in HepG2-IκBα(S/A) cells. As shown in figure 
3.1.7B, lack of NF-κB activation did not impair IL-1β-dependent serine 727 phosphorylation. 
Although STAT1-serine phosphorylation is intact in HepG2-IκBα(S/A) cells after IL-1β 
stimulation, IL-1β is not able to enhance IL-6-mediated SOCS3 expression in those cells. In 
other words, these data suggest that STAT1-serine phosphorylation is not responsible for the 
enhanced SOCS3 expression after treatment with IL-1β. 
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Figure 3.1.7: IL-1β-induced serine phosphorylation of STAT1 does not depend on NF-κB activation and 
thus is not responsible for the enhancing effect of IL-1β on IL-6-induced SOCS3 expression. 
(A) HepG2 cells were stimulated as described in the legend to figure 3.1.6. Whole cell lysates were prepared and 
proteins were subjected to SDS-PAGE. Left part: STAT1-serine phosphorylation was analyzed by Western-
blotting with antibodies specific for phosphoserine 727 of STAT1 (upper panel). Right part: STAT1-tyrosine 
phosphorylation was analyzed by Western blotting with antibodies specific for phosphotyrosine 701 of STAT1 
(upper panel). For loading controls, the membrane was stripped and re-probed with antibodies specific for 
STAT1 (lower panels). (B) HepG2 cells expressing IκBα(S/A) were treated as described for (A). 
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3.1.8 The enhancing activity of IL-1β on IL-6-induced SOCS3 expression depends 
neither on the p38 pathway nor on the JNK pathway 
IL-1β is known to activate NF-κB as well as MAPKs such as p38 and JNK [18, 19]. 
Activated p38 and JNK can phosphorylate numerous downstream transcription factors to 
regulate gene expression. Therefore, we first investigated whether the activation of p38 
mediates the enhancing effect of IL-1β on IL-6-induced SOCS3 expression. The amount of 
SOCS3 protein after stimulation with IL-1β and IL-6 was determined in HepG2 cells 
incubated with the p38-specific inhibitor SB202190 (figure 3.1.8A). IL-1β preincubation led 
to an increased IL-6-induced SOCS3 protein expression independent of the presence of 
solvent or the SB202190 inhibitor. The observation that blockade of the p38 pathway resulted 
in a reduced SOCS3 expression supports our previously data [121]. Activation of p38 through 
the phosphorylation at the Threonine 180 and Tyrosine 182 results in activation of 
downstream phosphatases such as MAP kinase phosphatase 1 (MKP1) [134]. This forms a 
classic feedback loop of p38 activity regulation. SB202190, a specific inhibitor of p38 
activity, by blocking the feedback inhibition through the p38-specific phosphatase activity, 
leads to enhanced phosphorylation of p38. Indeed, increased p38 phosphorylation was 
observed in HepG2 cells treated with SB202190 (figure 3.1.8B). Second, to explore a possible 
role of JNK activation in the enhancing effect of IL-1β, analogous experiments were 
performed. Similarly, prevention of JNK activation by the specific inhibitor (SP600125) led 
to a reduced SOCS3 expression by IL-6 (figure 3.1.8C). However, IL-1β still displayed the 
potential to increase the IL-6-induced SOCS3 expression in the presence of SP600125. The 
inhibition efficiency of SP600125 was monitered by c-Jun phosphorylation. Taken together, 
these data suggest that neither JNK activation nor p38 activation mediates the enhancing 
effect of IL-1β on IL-6-induced SOCS3 expression. 
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Figure 3.1.8: The protein kinase p38 does not contribute to the enhancing effect of IL-1β on IL-6-induced 
SOCS3 expression. 
(A) After pre-treatment with DMSO or SB202190 for 20 min HepG2 cells were stimulated with IL-6 (100U/ml), 
IL-1β (100U/ml) or both for additional 60 min. For IL-1β/IL-6 co-stimulation IL-1β was given 10 min prior to 
IL-6. SOCS3 protein was measured by immunoprecipitation and subsequent Western blotting as described in the 
legend to figure 3.1.6 (B) Identically treated HepG2 cells were used to confirm functionality of the SB202190 
inhibitor by monitoring phosphorylation of p38. Cellular extracts were prepared, proteins were separated by 
SDS-PAGE and analyzed by Western blotting with antibodies specific for the phosphorylated form of p38 
(upper panel). For loading controls, the membrane was stripped and re-probed with antibodies specific for p38 
(lower panel). (C) Similar experiments were performed as described in A. Instead of SB202190, 20 µM and 40 
µM SP600125 was pre-incubated for 20 minutes. (D) The inhibition efficiency of SP600125 was monitored by 
the phosphorylation of c-Jun. 
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3.1.9 NF-κB activated by IL-1β does not act through binding to the SOCS3 promoter 
To elucidate the mechanism by which NF-κB mediates the positive regulatory function of IL-
1β on IL-6-induced SOCS3 expression, putative NF-κB binding to the SOCS3 promoter was 
evaluated with a Chromatin Immunoprecipitation (ChIP) assay using p65-specific antibodies. 
Two regions within the SOCS3-promoter were found to harbor putative NF-κB sites by the 
MatInspector (Genomatix Software, München, Germany). The primers used in the ChIP 
assays were indicated in figure 3.1.9B. As a positive control, binding of NF-κB to the IκBα 
promoter was determined (figure 3.1.9A upper panel, left four bands). Applicability of the 
selected PCR-primers was confirmed by the input control (four bands on the right part of both 
panels). Unspecific binding of promoter fragments was controlled by a ChIP assay without 
antibodies (w/o antibodies). Figure 3.1.9A shows that no NF-κB binding to the SOCS3 
promoter was detectable in response to IL-1β, whereas NF-κB binding was confirmed for the 
IκBα-promoter. These results infer that NF-κB does not act directly through binding to the 
SOCS3-promoter but more likely indirectly by the induction of secondary effector proteins. 
 
 
 
Figure 3.1.9 A: NF-κB does not bind directly to the SOCS3 promoter. 
HepG2 cells were stimulated as described in the legend to figure 3.1.6. Chromatin immunoprecipitation was 
performed with antibodies specific for the p65 subunit of NF-κB. Binding of NF-κB to the SOCS3 promoter was 
determined by PCR with two different pairs of SOCS3-promoter specific primers. PCR conditions for these 
primers were tested for amplification of SOCS3 promoter fragments out of the input chromatin without 
immunoprecipitation. Efficiency of immunoprecipitation of NF-κB/DNA complexes was monitored with PCR-
primers specific for the IκB promoter. 
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CTGACCCCAG CCTGGGGTGT GAATGCCCCC TTCTCGGCCA CCTTTCCAGC 
TCCGGAGACA GCCATTCCCG CAGATCCCTG GCGTGCCTAT TCCAAGGCCT 
GGGCCGCGCA GCACCAAACT GCCCTCCCCT AGGAGACCCC AGGGCGCCCT 
CTGGCGGACG CGGGCCGTAG GTTGGGGCCA TCGTTCCACC TCGAGCTCTC 
CAGCCCGGCC GAGAGCACCT GGCCCAACCC ACACCGGACC AACCAGGTTT 
GCAGACCCCA GTGCATGAAA GCGTTTTCAT AGGGGAGGGG AGGGGGGCTC 
CACACTCGCG TCAGGGTTGG CAAAGAACCT GGCAGTGGGC CGAGGCTGGG 
TAGCTGCCAC GAAGGGGCGT CCCCTGCAGC CCTGGGTCTC CCCTCTGGAA 
TCTGCCCGCA GGTGACTGTC GCACGTCTCC AACCTCCGGC TCCCGGGTCT 
GACCCCAGCC CCGCTGCCTG GCTGTGGGGT AGCCCCACTT CCCTTTCGGC 
TGGCCCGGGC CGCCTGACCC GCAGTTGGGC CCTCGGGGAG GCCCGGGTGG 
CGGCGAGGGG GTGTCCCCGC GGGGTCCGGG AAAAGGGGAA GGGGAACCGG 
GAGGCTCTCC AGGTCGGCCT CCTAGAACTG CCCGCTCTCC CGAAGCGGCG 
CCCCCGCCTC TGCCAGAAAT CAGCCTTCTT AGAAGGGAGG GGGGTGGGGG 
GAAAGTGTGA ATGAGAAGTT GGGGGCGGAG CGCGCGGCGG GGAGGGGCCG 
CTGCCAGGAA CGCGCCGCCG GGGCTGGCGC CGCGCCCACC GGCCGCCTCG 
GCCGCCTCTC GTCGCGCTTT GTCTCCGCGC GCGTCCCTCC CGGTCCCTGC 
CCCTGCTCGC GGCCCGCCCT CGGCGCCCGC GGCCCCTCCC TCACCCTCCG 
CGCTCAGCCT TTCTCTGCTG CGAGTAGTGA CTAAACATTA CAAGAAGGCC 
GGCCGCGCAG TTCCAGGAAT CGGGGGGCGG GGCGCGGCGG CCGCCTATAT 
ACCCGCGAGC GCGGCCTCCG CGGCGGCTCC GACTTGGACT CCCTGCTCCG 
CTGCTGCCGC TTCGGCCCCG CACGCAGCCA GCCGCCAGCC GCCCGCCCGG 
CCCAGCTCCC GCCGCGGCCC CTTGCCGCGG TCCCTCTCCT GGTCCCCTCC 
CGGTTGGTCC GGGGGTGCGC AGGGGGCAGG GCGGGCGCCC AGGGGAAGCT 
CGAGGGACGC GCGCGCGAAG GCTCCTTTGT GGACTTCACG GCCGCCAACA 
TCTGGGCGCA GCGCGGGCCA CCGCTGGCCG TCTCGCCGCC GCGTCGCCTT 
GGGGACCCGA GGGGGCTCAG CCCCAAGGAC GGAGACTTCG ATTCGGGACC 
AGGTAGGAAG GAGGAGCGCG GCGTGGGGAG GGGTCTCGCT CAGTCCCGGG 
AGCTTTTCCC GGTTTCCCCT CCCCTTCCCG GGTCATTCCC GGCAGGGAGG 
TGACGAGGTA GGGGCAGAGC GGATGGAAGC CGGAGATCCC AGGTTCCCGG 
AATACTCCGG CTGGGGCCTT CGGGCTTCTC CTGTCCCCTC CCTACCCCCG 
TGCCTCGGGT TTCTCCCTCC GTCCACACCG CCCGGGGCTA CTGGACTGAG 
CGGCGCCCAG GCAGTCCCGG GGGCCCTTCT CCTGCTCCCC ACCCGGCCAC 
ACTCCTGGAG ACCTAACTTC CGCGCGCGAG TTTCCCACGC TGCGCCCTTG 
CAGTGCGCGC CTGGGAAGGG GCTGCCCGGG GCCACCCTGC CGGCAGGGGC 
GGGAGCCGTG CGGGCTCCGT GAGGCGCCTG GATCGGAGCG CGGGCCCAGG 
AGAGGGCCCC CGGGGCAGTG GGTGCCCCAG TCGCTCGGCG AAGGCAGGGG 
AGCCGGGGCG GGCCGGGCGC GCTGGAGGGT TCCGGGCACT CAACGCGCTC 
GCGCCTTCCT CTCCGCAGCC CCCCGGGATG CGGTAGCGGC CGCTGTGCGG 
AGGCCGCGAA GCAGCTGCAG CCGCCGCCGC GCAGATCCAC GCTGGCTCCG 
  TGCGCCATGG TCACCCACAG CAAGTTTCCC GCCGCCGGGA 
 
Figure 3.1.9B: Sequence of the 5’-flanking region of the human SOCS3 gene. 
 
N : ChIP distal primers  
N : ChIP proximal primers  
T  : putative transcription starting site 
N : putative STAT binding sites 
N : putative NF-κB binding sites 
N : translation starting site 
TATATA: TATA box 
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3.1.10 The enhancing effect of IL-1β on IL-6-dependent SOCS3 expression requires 
protein synthesis 
The hypothesis that IL-1β does not act directly on the SOCS3-promoter but rather through the 
induction of downstream effector proteins and thus requiring new protein synthesis was tested 
next. The effect of the protein synthesis inhibitor cycloheximide (CHX) on the IL-6-induced 
SOCS3 mRNA expression in presence of IL-1β was determined by Northern blotting. Figure 
3.1.10A shows that CHX-treatment enhanced IL-6-induced SOCS3 expression which could 
be explained by the loss of SOCS3 feedback inhibition (compare lanes 3 and 7). Furthermore, 
co-stimulation with IL-1β enhanced IL-6-dependent SOCS3 mRNA expression in DMSO-
treated cells (compare lanes 3 and 4) but not in CHX treated cells (compare lanes 7 and 8). 
CHX treatment rather reduced SOCS3 mRNA levels in response to IL-1β plus IL-6, similar 
as shown in response to the block of NF-κB activation in figure 3.1.6. To exclude any effect 
of CHX-treatment on IL-1β-induced NF-κB activation, NF-κB DNA binding activity in the 
presence and absence of CHX was monitored in an EMSA. As shown in figure 3.1.10B CHX 
treatment did not affect NF-κB activation. These data support the idea that IL-1β acts through 
NF-κB by inducing the synthesis of (a) regulatory protein(s) which finally act(s) positively on 
SOCS3 expression. 
Figure 3.1.10: De novo protein synthesis is required for the enhancing effect of IL-1β on IL-6-induced 
SOCS3 expression.  
(A) After pre-treatment with DMSO or cycloheximide for 20 min HepG2 cells were stimulated with IL-6 
(100U/ml), IL-1β (100U/ml) or both for additional 60 min. For IL-1β/IL-6 co-stimulation IL-1β was given 10 
min prior to IL-6. Total mRNA was isolated and analyzed by Northern blotting with a specific probe for SOCS3 
(upper panel). As loading control, the membrane was re-stained with a GAPDH-specific probe (lower panel). (B) 
HepG2 cells were stimulated with 100 U/ml IL-1β in the presence or absence of cycloheximide. Nuclear extracts 
were prepared and tested for NF-κB DNA binding activity by EMSA. 
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3.1.11 IL-1β does not affect SOCS3 protein degradation but it stabilizes SOCS3 mRNA 
Instead of increasing IL-6-dependent induction of SOCS3, IL-1β could also affect the stability 
of SOCS3 protein or mRNA to increase SOCS3 levels in the cell. To test whether IL-1β 
stabilizes SOCS3 protein, the time-dependent loss of SOCS3 protein was compared in the 
presence or absence of IL-1β (figure 3.1.11A). SOCS3 protein expression in HepG2 cells was 
induced by stimulation with IL-6 for 40 min. Afterwards, IL-6 was removed and 
cycloheximide was added to the medium to avoid de novo protein synthesis. The loss of 
SOCS3 protein within the following 90 min was compared in the absence (left part) or 
presence (right part) of IL-1β. No obvious effect of IL-1β treatment on the degradation of 
SOCS3 was observed suggesting that IL-1β does not stabilize SOCS3 protein. 
 
Another possibility would be that IL-1β acts by stabilizing SOCS3 mRNA. To analyze the 
decrease of SOCS3 mRNA in the absence or presence of IL-1β, analogous experiments as 
described in figure 3.1.11A were performed. SOCS3 mRNA was induced by stimulation of 
HepG2 cells with IL-6 for 30 min (figure 3.1.11B). Ongoing mRNA synthesis was blocked by 
eliminating IL-6 from the medium and by addition of actinomycin D to the medium. Block of 
IL-6-mediated SOCS3 transcription by actinomycin D is shown on the right panel of figure 
3.1.11B. The decrease in SOCS3 mRNA within 90 min of actinomycin D incubation was 
monitored in the absence (left part) or presence (right part) of IL-1β by Northern blotting (left 
panel). Most importantly, whereas SOCS3 mRNA was rapidly degraded in the absence of IL-
1β, SOCS3 mRNA was apparently stabilized in IL-1β-treated cells. We conclude from these 
results that IL-1β is able to increase SOCS3 expression by stabilizing SOCS3 mRNA. 
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Figure 3.1.11: IL-1β stabilizes SOCS3 mRNA but not the SOCS3 protein. 
(A) HepG2 cells were stimulated with 100 U/ml IL-6 for 40 minutes. Subsequently cells were washed and 
cultivated for additional 20 min in IL-6-free medium containing cycloheximide (25 µM) for 20 min. Afterwards, 
100 U/ml IL-1β were added to the medium for the times indicated. SOCS3 protein was monitored as described 
for figure 3.1.5. (B) HepG2 cells were stimulated with 100 U/ml IL-6 for 30 minutes. Subsequently cells were 
washed and cultivated for additional 20 min in IL-6-free medium containing actinomycin D (4 µM) for 20 min to 
block transcription. Afterwards, 100 U/ml IL-1β were added to the medium for the times indicated. SOCS3 
mRNA (upper left panel) and GAPDH mRNA (lower left panel) were monitored as described for figure 3.1.5. 
To show that actinomycin D blocks IL-6-induced SOCS3 mRNA synthesis, HepG2 cells were stimulated with 
IL-6 (right panel, middle lane) or pre-incubated with actinomycin D (4 µM) for 20 min and afterwards 
stimulated with 100 U/ml IL-6 in the presence of actinomycin D for 30 min.  
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3.1.12 SOCS3 expression contributes to the inhibitory activity of IL-1β on gp130-
mediated signalling 
To examine the impact of SOCS3 expression in the context of a cross-talk between IL-1β and 
IL-6 signalling, knock down studies were done by using SOCS3-siRNA. For this purpose, 
HepG2 cells were transiently transfected with vectors coding for SOCS3 siRNA. To be able 
to specifically stimulate the population of transfected cells, expression vectors encoding 
chimeric receptors composed of the extracellular part of the EpoR and the transmembrane and 
cytoplasmic parts of gp130 were co-transfected. This well established chimeric receptor 
system (figure 3.1.12A, right panel) allows to analyze gp130-dependent signalling in response 
to Epo [90, 135]. As shown in figure 3.1.12A, the generated SOCS3-siRNA construct 
efficiently knocked down the expression of SOCS3. Stimulation of the transfected HepG2 
cells with Epo led to SOCS3 expression (lane 2). In contrast, cells additionally expressing 
SOCS3-siRNA showed drastically reduced SOCS3 levels in response to Epo, indicating that 
the SOCS3-siRNA is functional. The effect of IL-1β on Epo-induced reporter gene expression 
was evaluated in the absence or presence of SOCS3-siRNA (figure 3.1.12B). Epo stimulation 
resulted in a significant induction of the STAT3-driven reporter gene construct (2nd bar), 
whereas the expression was inhibited to 50% in the presence of IL-1β (compare 2nd and 4th 
bars). These results are quite similar to those already presented in figure 3.1.1A. Cells 
additionally expressing SOCS3-siRNA showed a drastically increased reporter expression due 
to the lack of SOCS3-mediated feedback inhibition (compare bars 2 and 6). Interestingly, IL-
1β was hardly able to inhibit expression of the reporter gene in these cells (compare bars 6 
and 8) suggesting SOCS3 to play an important role in the IL-1β-mediated inhibition of IL-6-
induced gene expression. 
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Figure 3.1.12: Blockade of SOCS3 expression counteracts the inhibitory effect of IL-1β. 
(A) To monitor SOCS3 siRNA function HepG2 cells were co-transfected with vectors expressing SOCS3 siRNA 
or control vectors together with expression vectors of EpoR/gp130 chimeric receptors. After transfection, cells 
were stimulated with Epo (7 U/ml) for 50 min and SOCS3 expression was analyzed by immunoprecipitation and 
Western blotting as described for figure 3.1.5. (B) HepG2 cells were co-transfected with vectors expressing 
SOCS3 siRNA or control vector together with the STAT3-responsive SIE-luciferase reporter gene construct 
containing two STAT3 binding sites, expression vector of EpoR/gp130 chimeric receptors and an expression 
vector for β-galactosidase. After transfection, cells were stimulated with 100 U/ml IL-1β or Epo (7 U/ml) or both 
for 16 h. Luciferase activity in cellular extracts of these cells was determined and normalized to β-galactosidase 
activity, as outlined in Materials and Methods.  
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3.2 SOCS3 expression in response to inflammatory stimuli in vivo  
3.2.1 Kinetics of Lipopolysaccharide (LPS)- and turpentine-induced SOCS3 expression 
in wild-type mice 
Various inflammatory stimuli and cytokines can induce SOCS3 in vitro [75, 103]. Therefore, 
it was of interest to find out whether the patterns of SOCS3 mRNA expression in the livers of 
mice differ depending on the inflammatory stimulus applied. Injection of turpentine and 
LPS/endotoxin served as models of aseptic and bacterial inflammation, respectively. IL-6-
deficient C57BL/6-mice were sacrificed at different time points up to 24 hours after initiation 
of the acute phase reaction and SOCS3 mRNA levels were determined. Basal SOCS3 
expression was low. As can be seen in figure 3.2.1, LPS (filled circles) caused a rapid and 
strong induction of SOCS3 mRNA which peaked (up to 45-fold) at 1 hour and decreased 
continuously thereafter. From 14 hours onwards, an approximately 5-fold increase in gene 
expression was maintained. On the other hand, turpentine-induced SOCS3 mRNA expression 
was less effective (approx. 30-fold induction) and it did not peak until 8 hours post-
stimulation. However, increased expression of SOCS3 upon turpentine challenge was 
maintained for a longer time span, with a 12-fold induction still detectable at 24 hours. 
  
Figure 3.2.1: Kinetics of LPS- and turpentine-induced expression of SOCS3 in wild-type mice.  
C57BL/6 mice were treated with either 125 µg LPS (circles) or 100 µl turpentine (squares) for the times 
indicated as described in Materials and Methods. Hepatic SOCS3 mRNA levels were determined and adjusted to 
the basal SOCS3 mRNA amounts of untreated animals. The average values of three to four animals at each time 
point were plotted.  
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3.2.2 SOCS3 gene expression in IL-6-deficient mice during an aseptic and endotoxin-
induced acute phase reaction 
IL-6 is the key cytokine during the hepatic acute phase reaction, regulating the expression of 
the APPs [136]. Moreover, IL-6 is a strong inducer of SOCS3, and SOCS3 in turn tightly 
controls IL-6 signalling. However, the impact of IL-6 on the induction of SOCS3 mRNA in 
response to aseptic and bacterial inflammatory stimuli in vivo is not well understood. To 
address this issue, both IL-6-deficient mice (IL-6-/-) and the corresponding wild-type (WT) 
mice were challegend with the two different inflammatory stimuli, LPS and turpentine, 
respectively. Subsequently, SOCS3 transcripts were measured and compared in the livers of 
WT mice and IL-6-/- mice.  
 
The basal level of SOCS3 mRNA expression in unchallenged IL-6-/- mice was low and 
unchanged in comparison to WT mice. When challenged with turpentine, IL-6-/- mice, as 
opposed to WT mice, showed virtually no increase in SOCS3 mRNA levels up to 14 hours 
after stimulation, and after 24 hours, only a minor SOCS3 mRNA up-regulation of less than 
5-fold was detectable (figure 3.2.2A). 
 
When endotoxin —to mimic bacterial infection— was administrated (figure 3.2.2B), the early 
dramatic increase in SOCS3 gene induction at one hour post-injection in wild type mice was 
absent in IL-6-/- mice. In contrast to the total loss of SOCS3 mRNA expression in turpentine-
treated IL-6-/- mice, stimulation with LPS led to a significant increase in SOCS3 mRNA 
despite the IL-6-deficient genotype; that increase, however, was considerably reduced for at 
least 8 hours when compared with the high SOCS3 expression levels in the corresponding 
LPS-treated WT mice. From 14 hours onwards, the levels of SOCS3 mRNA in IL-6-/- mice 
reached that of the wild type mice. 
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Figure 3.2.2: SOCS3 gene expression in IL-6-deficient mice during aseptic and edotoxin-induced acute 
phase reaction.  
IL-6-deficent mice (grey columns) and wild-type mice (black columns) were treated with either 100 µl 
turpentine (figure 3.2.2A) or 125 µg LPS (figure 3.2.2B). Livers were excised at the times indicated. After 
extraction of total RNA SOCS3 mRNA levels were determined and adjusted to the basal SOCS3 mRNA amount 
of untreated wild-type animals. For turpentine treatment, at each time point three animals of either genotype 
were sacrificed and used to calculate the mean values plotted in the graph. Four animals per time point were 
considered for the mean values of LPS-treated animals. 
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3.2.3 Inflammation-induced SOCS3-protein levels in wild-type and IL-6-deficient mice 
To confirm that the induction of SOCS3 mRNA and the respective differences observed 
between WT and IL-6-deficient mice are also reflected in the protein level, we analyzed 
SOCS3 protein in liver cell lysates by immunoprecipitation and Western blotting. No SOCS3 
protein could be detected in unstimulated mice of both genetic strains (figures 3.2.3A and 
3.2.3B). Eight hours after stimulation with turpentine, WT mice showed clearly detectable 
levels of SOCS3 protein which were conserved at 14 hours (figure 3.2.3A). The kinetics 
match the data of increased SOCS3 mRNA-levels from 2 hours onwards. Corresponding to 
the strong and rapid endotoxin-induced increase in SOCS3 mRNA after 1 hour, high levels of 
SOCS3 protein were already present 2 hours post stimulation with LPS (figure 3.2.3B). 
 
In IL-6-/- mice, turpentine-induced SOCS3 protein expression was severely impaired at any 
time point post-stimulation (figure 3.2.3A), which is in line with the mRNA data. Endotoxin 
was able to increase SOCS3 protein in IL-6-/- mice. However, the increase was delayed and 
reduced compared with the corresponding LPS-treated WT mice (figure 3.2.3B). Similar to 
the mRNA data with highest differences in SOCS3 expression at 1 hour, SOCS3 protein 
levels varied the most at early time points (2 hours post stimulation with LPS). 
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Figure 3.2.3: Inflammation-induced SOCS3-protein levels in wild-type and IL-6-deficient mice.  
Wild-type mice and IL-6-deficent mice  were treated with either 100 µl turpentine or 125 µg LPS. Livers were 
excised and homogenized at the times indicated. The total liver lysates were immunoprecipitated with SOCS3 
antibodies (kind gift from J. Johnston). The amouts of precipitated SOCS3 from wild-type (WT) and IL-6-
deficient (KO) mice treated with turpentine (figure 3.2.3A) or LPS (figure 3.2.3B) were determined by Western 
blotting analysis with another anti-SOCS3 antibody.   
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3.2.4 LPS-induced SOCS3 gene expression in mice deficient for IL-6 and TNFR1 
While there was no SOCS3 gene induction in IL-6-deficient animals treated with turpentine, 
in LPS-treated IL-6-deficient mice, a mild inductive effect could be observed, particularly at 
delayed time points (figure 3.2.2B). Although LPS releases a wide range of mediators, TNF-α 
is known to play a key role in LPS-induced signalling and has been shown to induce SOCS3 
expression in vitro [113]. TNF-α, a pro-inflammatory cytokine, plays an important role in 
regulation of autoimmunity and inflammation. TNF-α exerts its bilogical activities via its two 
receptors, the 55-KDa TNF receptor 1 (TNFR1) and the 75-KDa TNF receptor 2 (TNFR2) 
However, it is believed that TNFR1 plays the predominant role in the TNF signaling [137, 
138]. To assess the contribution of TNF-α on the SOCS3 induction during LPS-mediated 
inflammation, SOCS3 mRNA induction was investigated in IL-6 and TNF receptor 1 double 
knock out mice. As opposed to the mild inductive effect on SOCS3 gene induction in IL-6-/- 
mice 14 h after stimulation with LPS, the double knock out mice exhibited the same low 
SOCS3 mRNA expression as seen in untreated control mice (figure 3.2.4). 
Figure 3.2.4: Endotoxin-induced SOCS3 gene expression in IL-6-/-TNFR1-/-deficient mice.  
Wild-type mice, IL-6-deficient mice, and IL-6/TNFR1 double knock out mice were treated with 125 µg of LPS 
for 14 hours or left untreated. After extraction of total RNA SOCS3 mRNA levels were determined and adjusted 
to the basal SOCS3 mRNA amount of untreated wild-type animals as described for figure 3.2.2. 
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4 Discussion  
Under physiological conditions, cellular functions are regulated by the action of many 
cytokines. The cross-talks among different cytokine-signalling pathways are crucial for 
physiological processes like T cell differentiation, insulin resistance, immunoregulation, and 
acute phase protein gene induction. The feedback inhibitor SOCS3 has been implicated as a 
key regulator in the cross-talk between different cytokines. For instance, IL-10 exerts its anti-
inflammatory activity, at least in part, by inhibiting the activity of pro-inflammatory cytokines 
such as IFNs and IL-6. The inhibitory activity of IL-10 on IFNs and IL-6 signalling is largely 
mediated through the induction of SOCS3. Of note, IL-10 signalling is not affected by SOCS3 
since the IL-10R lacks a SOCS3 binding site [112, 139]. In addition, a variety of 
proinflammatory cytokines have been shown to be capable of inhibiting insulin signalling, 
which may contribute to the course of insulin resistance. Recently, SOCS3 has been shown to 
mediate the inhibitory effect of  IL-1β on insulin signalling [131].  
 
Another example for the cross-talk of cytokines is the regulation of acute phase protein gene 
induction. It is believed that APP synthesis in liver is regulated at the transcriptional level by 
different cytokines. IL-1 and IL-6 are the main inflammatory mediators involved in this 
transcriptional induction, acting synergistically to activate a subset of APPs which are known 
as type I APPs. In contrast, another group of genes, so called type II APPs, are solely 
responsive to IL-6-type cytokines but regulated negatively by IL-1β. In the context of the 
cross-talk between IL-1β and IL-6, the function of SOCS3 and its regulation remained 
unclear. On one hand, it might be that IL-1β inhibits IL-6-induced type II APP expression 
through induction of SOCS3. On the other hand, it is possible that IL-1β negatively regulates 
IL-6-induced SOCS3 expression, similar to that of type II APPs. These two possibilities 
would result in totally opposite effects of IL-1β on APP gene expression. To address this 
issue, the regulation of IL-6-induced SOCS3 expression by IL-1β was studied in detail in the 
first part of this thesis. 
 
Turpentine- and LPS-induced inflammatory reactions are well-established animal models for 
aseptic and bacterial inflammation, respectively. Both inflammatory stimuli lead to an acute 
phase reaction characterized by fever, pain, anorexia, an stimulation of the adrenocortical 
axis, leukocytosis and other hematopoietic changes and an increased expression of hepatic 
acute phase proteins [140]. These inflammatory cascades are tightly controlled by the 
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concerted action of different mediators released under inflammatory conditions.  SOCS3 has 
been shown to be induced by a variety of inflammatory mediators in vitro including both pro-
inflammatory and anti-inflammatory cytokines. Among these cytokines, IL-6 has been shown 
to play a central role in hepatic acute phase protein induction during inflammatory processes 
[3, 141]. To determine whether IL-6 is crucial for SOCS3 induction in vivo, turpentine- and 
LPS-mediated SOCS3 induction in WT and IL-6-/- mice was analyzed in the second part of 
this thesis. 
4.1 IL-1β-mediated dual regulation of IL-6-induced SOCS3 expression 
Recently, SOCS3 has been identified as the mediator of the inhibitory effect of TNF-α and 
LPS on IL-6 signalling in macrophages [113]. IL-1β has been shown to inhibit the IL-6 
signalling in hepatocytes [6]. However, the results of this thesis show that IL-1β alone does 
not induce SOCS3 gene expression in hepatocytes. This is contradictory to a previous report 
showing SOCS3 expression in rat hepatocytes in response to IL-1β exposure for more than 8 
hours [130]. This discrepancy is likely due to the existence of an autocrine IL-6 loop in the rat 
primary hepatocytes after long term IL-1β treatment. The results presented here show a dual 
effect of IL-1β on IL-6-induced SOCS3 expression in human hepatocyte. IL-1β was found to 
antagonize IL-6-induced SOCS3 promoter activity by activating NF-κB. A similar inhibition 
of IL-6-mediated expression of acute phase proteins such as fibrinogen and α2M upon IL-1β 
stimulation has been reported earlier [6-8]. Surprisingly, IL-1β did not exert its inhibitory 
action on the SOCS3 promoter immediately after IL-6 stimulation. Instead, a slight but 
reproducible increase in SOCS3 promoter activity was observed by costimulation of IL-1β. 
Most importantly, this IL-1β/IL-6 synergism could also be confirmed and was even more 
obvious for endogenous SOCS3 expression in a time- and dose-dependent manner for IL-1β 
(figure 3.1.5). The inhibitory effect of IL-1β in the later phase of IL-6 stimulation can be 
explained by the enhanced SOCS3 induction leading to increased feedback inhibition.  
4.2 The inhibition of IL-1β on IL-6-mediated STAT3 activation is 
independent of NF-κB activation 
Although the cross-talk between IL-1β and IL-6 has been studied intensively, the question of 
how IL-1 inhibits IL-6-mediated STAT3 activation remained unclear. It has been reported 
that IL-6-mediated STAT1 but not STAT3 DNA binding activity in HepG2 cells was 
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suppressed by pretreatment with IL-1β [132]. In contrast, in this thesis, upon IL-6 stimulation 
no STAT1/DNA complex was observed in the EMSA experiments using the mSIE probe. 
Instead, pretreatment of HepG2 cells with IL-1β impaired IL-6-initiated STAT3 
phosphorylation as well as the DNA binding activity (figure 3.1.3). These contradicting 
observations could be due to different cellular fractions and preparation methods used in the 
EMSAs. Shen et al. [132] used total cell lysates for their EMSAs, whereas detergent-free 
buffer was used for nuclear preparation in our study. Recently, it could be shown by Haan et 
al. that different buffer systems affect the formation of STATs/DNA complexes [142]. 
Consistent with the results presented in this thesis, Zhang et al. [8] and Bode et al. [7] have 
shown that the overall DNA binding activity of STAT3 with the mSIE probe was also 
impaired, although both groups focused on another mechanism of the inhibition of IL-1β on 
IL-6 signalling: activated NF-κB competes with STAT3 for the overlapping binding sites 
within the fibrinogen promoter and the α2M promoter, respectively. P38 activation has been 
proposed to mediate the rapid inhibitory effect of IL-1β on IL-6-mediated STAT3 activation 
[115]. The inhibition of IL-6-induced STAT3 activation by IL-1β has also been reported to 
occur in the absence of new protein synthesis, indicating that SOCS3 expression is not 
essential for the inhibitory effect of IL-1β on IL-6-induced STAT3 activity. However, the 
molecular mechanism underlying the p38-mediated inhibition of IL-6-initiated STAT3 
activation by IL-1β remains elusive. To examine the possible role of NF-κB in the inhibitory 
effect of IL-1β on IL-6-mediated STAT3 activation, the activation of STAT3 in wild type 
cells and NF-κB-activation-deficient cells was compared in this thesis. Regardless of the 
absence or presence of NF-κB activation, IL-1β is able to suppress the IL-6-mediated STAT3 
activation suggesting that NF-κB activation is dispensable for the fast inhibitory effect of IL-
1β on STAT3 activation (figure 3.1.3). Thus, further investigations need to be done to answer 
the question of how IL-1β mediates the inhibiton of IL-6-induced STAT3 activation. 
4.3 NF-κB acting as a molecular switch for the dual effects of IL-1β on IL-
6-induced SOCS3 expression 
As discussed above, a dual role of IL-1β on IL-6-mediated SOCS3 induction has been 
established in this study. Strikingly, both the synergistic and antagonistic effects of IL-1β on 
SOCS3 expression depends on NF-κB. Prevention of the IL-1β-induced NF-κB activation 
blocks the inhibitory effect of IL-1β on IL-6-mediated SOCS3 promoter activity in the later 
phase of IL-6 stimulation. Conversely, IL-1β fails to increase early IL-6-mediated 
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endogenous SOCS3 expression in the absence NF-κB activation. Instead, pretreatment of 
hepatoma cells lacking NF-κB activation with IL-1β leads to a reduced IL-6-dependent 
SOCS3 expression, which reflects the NF-κB-independent inhibition of STAT3 
activation/tyrosine phosphorylation by IL-1β.  
 
SOCS3 is an immediate early response gene induced by IL-6 and acts as a classic feedback 
inhibitor for IL-6 signalling. However, in the reporter gene assays except specially indicated, 
the cells were often stimulated with cytokines for more than 16 hours and then the luciferase 
activities were measured. Thus, it was more relevant to check the regulation of IL-1β on IL-6-
induced SOCS3 mRNA and protein expression rather than the luciferase expression driven by 
SOCS3 promoter. Interestingly, unlike α2M and the fibrinogen, the IL-6-induced SOCS3 
mRNA as well as protein expression was found to be augmented by IL-1β in an NF-κB-
dependent manner. Since NF-κB is a transcription factor, it is plausible that activated NF-κB 
binds directly to the SOCS3 promoter leading to enhanced SOCS3 expression. However, 
binding of NF-κB to the SOCS3 promoter was detected neither in an EMSA (data not shown) 
nor in ChIP assays. These results argue against a direct function of NF-κB on the SOCS3 
promoter. They rather favour the induction of one or more not yet identified IL-1β-induced 
proteins that finally -in concert with IL-6- support SOCS3 expression. Indeed, this idea is 
confirmed by the observation that de novo protein synthesis was found to be required for IL-
1β to exert its enhancing effect on SOCS3 gene induction (figure 3.1.9A). Inhibition of 
protein biosynthesis counteracts the enhancing activity of IL-1β on SOCS3 expression, 
similar as the observed response to impaired NF-κB activation (figure 3.1.6).  
 
Most recently, preliminary data [Albrecht et al. unpublished data] suggest that treatment of 
HepG2 cells or rat primary hepatocytes with IL-1β leads to an association of STAT3 with 
p65. This observation is consistent with a previous report [143]. So far, the requirements for 
the complex formation and the significance of the complex for the cross-talk between IL-1β 
and IL-6 are not well understood. One could speculate that the association of p65 with a 
STAT3 monomer could prevent the phosphorylation of STAT3 and its subsequent nuclear 
translocation, which would result in an inhibition of transcriptional activity of STAT3. 
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4.4 Possible mechanisms of IL-1β-mediated enhanced SOCS3 expression  
Although IL-6-mediated STAT3 tyrosine phosphorylation and DNA binding activity are 
impaired by co-stimulation with IL-1β, IL-1β enhances the IL-6-induced SOCS3 mRNA and 
protein. Enhanced SOCS3 expression could be a result of enhanced serine phosphorylation of 
STAT1 and/or STAT3. Serine phosphorylation of both transcription factors has been shown 
to boost the transcriptional activity [45]. Recently, Stark and collaborators described that 
STAT1 serine phosphorylation was induced by IL-1β in an IRAK-dependent manner [133]. 
The results presented in this thesis demonstrate that NF-κB activation is crucial for the 
enhancing effect of IL-1β on IL-6-induced SOCS3 expression. To clarify a possible 
contribution of serine phosphorylation on the enhancing effect of IL-1β, we examined 
whether IL-1β-induced STAT1 serine phosphorylation is dependent on NF-κB. Indeed, 
consistent with the results of Nguyen et al. IL-1β strongly induces STAT1 serine 
phosphorylation whereas IL-6 induces a strong STAT1/3 tyrosine phosphorylation [133]. 
However, loss of NF-κB activation did not alter STAT1 serine phosphorylation but reversed 
the positive role of IL-1β on endogenous SOCS3 expression suggesting that STAT1 serine 
phosphorylation is not linked to the augmenting effects of IL-1β on SOCS3 expression. 
Because of the current limitation of suitable antibodies against serine-phosphorylated STAT3, 
the STAT3 serine phosphorylation could not be examined in this study. Whether STAT3 
serine phosphorylation plays a role in the cross-talk between IL-1β and IL-6 needs further 
investigation. Besides serine and tyrosine phoshorylation, very recently STAT3 has also been 
shown to be subject to acetylation upon IL-6 and Oncostain M stimulation [49, 50]. 
Acetylation of STAT3 leads to the recruitment of co-activators to enhance transactivation 
activity. It will be of interest to clarify whether STAT3 is acetylated upon IL-1β treatment. 
 
Moreover, IL-1β is a strong MAPK activator. Blocking the p38 and the JNK pathways by 
specific inhibitors, respectively, results in decreased IL-6 induced SOCS3 expression 
suggesting that these two cascades are crucial for the maximal IL-6-induced SOCS3 induction 
(figure 3.1.8). On the other hand, blockade of the p38 and JNK pathways does not influence 
the supporting effect of IL-1β on IL-6-induced SOCS3 expression suggesting that the 
enhancing effect of IL-1β on IL-6-induced SOCS3 expression depends neither on p38 nor on 
JNK activation.  
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Instead of enhancing the induction of SOCS3 gene expression, the synergistic effect of IL-1β 
on SOCS3 expression could also be due to stabilization of SOCS3 mRNA or protein. SOCS 
proteins can interact with elongin B/C to form an E3 ligase complex through its conserved 
SOCS box. This interaction not only promotes the SOCS-box-targeted proteins for 
proteasome-mediated degradation but also stabilizes the SOCS proteins [98-100, 144]. Post-
translational modification of SOCS3 i.e. phosphorylation of SOCS3 at tyrosine residues 204 
and 221 within the conserved SOCS box disrupts the interaction between SOCS3 and elongin 
C  and in turn leads to proteasome-mediated SOCS3 destruction [102]. The results presented 
in this thesis show no obvious change of SOCS3 protein stability after addition of IL-1β.  
 
It is known that a number of protooncogene and cytokine mRNAs can be stabilized by 
extracellular stimuli. Strikingly, preincubation with IL-1β significantly slows down the decay 
of SOCS3 mRNA (figure 3.1.11). From the current knowledge, this is the first time that 
SOCS3 mRNA stabilization is attributed to the up-regulation of SOCS3 expression. 
Clarifying the molecular mechanism through which IL-1β stabilizes the IL-6-induced SOCS3 
mRNA would advance the understanding of the regulation of SOCS3 expression. This issue is 
subject of ongoing research and will be discussed in more detail in the “outlook section”. 
 
LPS and CpG activate toll-like receptor 4 (TLR4) and 9 (TLR9), respectively. Both pathogens 
have been described to induce SOCS3 in immune cells. But the mechanisms remain unknown 
[113, 145]. It has been shown that TLR-mediated responses to distinct TLR ligands involve 
both MyD88-dependent and -independent pathways, which leads to the activation of MAPK 
and NF-κB. Recent studies suggest that the MyD88-independent pathway activates the 
transcription factor IRF-3 [146]. Activated IRF-3, in turn, translocates from the cytoplasm to 
the nucleus, resulting in the transcriptional activation of IFN-β. Secreted IFN-β subsequently 
mediates the MyD88-independent TLR responses. IL-1R signalling events share similarity 
with TLR signalling since both receptors contain a conserved TIR domain in their 
cytoplasmic tails. However, no secreted IFN-β was detected upon IL-1β treatment in HepG2 
cells (data not shown) demonstrating that IL-1β does not act through IFN-β to enhance the IL-
6-induced SOCS3 expression.  
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4.5 Enhanced SOCS3 expression contributes to the inhibiton of IL-1β on 
IL-6 signalling 
From the reported literature data, it is evident that IL-1β can modulate the IL-6 signalling 
cascade at different levels:  
— suppression of IL-6-mediated STAT3 activation  
— binding of activated NF-κB to the fibrinogen promoter and the α2M promoter and  
— induction of SOCS proteins in several cells types.  
In this thesis, it is shown that IL-1β alone does not induce SOCS3 expression in hepatocytes. 
However, a synergistic effect of IL-1β on IL-6-induced SOCS3 expression was observed. It 
was examined if the increased SOCS3 expression contributes to the inhibitory effect of IL-1β 
on IL-6 signalling. The blockade of SOCS3 expression with siRNA led to the loss of the 
inhibitory effect of IL-1β on IL-6-mediated signalling. This observation clearly indicates that 
enhanced SOCS3 expression contributes to the inhibiton of IL-1β on IL-6 signalling. 
   
The results obtained in this thesis together with the data reported in the literature enable us to 
provide a model which comprises the multiple levels of cross-talk between IL-1β and IL-6 
(figure 4.1). IL-1β has a dual, time-dependent regulatory function on IL-6-induced SOCS3 
expression. It enhances early IL-6-induced SOCS3 expression through two distinct 
mechanisms. One involves the activation of NF-κB and it seems that NF-κB does not directly 
bind to the SOCS3 promoter but rather acts through the induction of (a) further regulatory 
protein(s) ○1 . In addition, the degradation of SOCS3 mRNA  is inhibited by IL-1β d. This 
amplified SOCS3 expression explains the later inhibitory effect of IL-1β on IL-6-induced 
SOCS3 promoter activity: The increased SOCS3 amount in the cell after co-stimulation with 
IL-1β leads to enhanced inhibition of IL-6 signalling and consequently to intensified 
inhibition of IL-6-induced SOCS3 expression at later times e. Additionally, IL-1β 
counteracts STAT3 activation independent of NF-κB activation ○4 . IL-1β-induced p38 
activation, JNK activation and STAT1 serine phosphorylation are not involved in the up-
regulation of SOCS3 expression (not included in the schema).  
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Figure 4.1: Schematic representation of regulation of IL-6-induced SOCS3 expression by IL-1β; activated 
transcription factors are marked by an asterisk. 
4.6 IL-6 is crucial for the SOCS3 induction in local inflammation in vivo 
Recently, LPS was shown to directly induce SOCS3 expression via TLR4 signalling in a 
MyD88-dependent manner in macrophage cells [107]. Alternatively, after LPS administration 
numerous cytokines [147] such as TNF-α, IL-1β, and IL-6 are released. These cytokines have 
been shown to induce SOCS3 [75, 103]. However, the individual contribution of those 
cytokines to SOCS3 expression during LPS-induced inflammatory processes is unknown. The 
use of IL-6-deficient mice allowed us not only to elucidate the relevance of IL-6 but also to 
estimate to which extent LPS-released cytokines or direct toll-like receptor signalling 
contribute to SOCS3 induction in vivo. Since turpentine administration initiates only a local 
inflammatory process mainly mediated by IL-1β and IL-6, it is ideal to analyze the role of 
these two cytokines in respect to SOCS3 induction in the turpentine-induced inflammation 
model [140, 147-149]. In the first set of experiments in this study with mice, SOCS3 mRNA 
induction was compared in both LPS- and turpentine-induced inflammation. It could be 
shown that LPS is a stronger inducer of SOCS3 mRNA than turpentine. Furthermore, LPS 
exerts its effect more rapidly than turpentine. This finding is in line with previous data 
showing delayed and quantitatively lower turpentine-induced acute phase protein mRNA 
induction in rats [3, 150, 151]. These differences are probably due to the initial local 
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inflammatory reaction after subcutaneous application of turpentine leading to IL-1β-mediated 
production and release of IL-6 into the circulation with subsequent APP synthesis in 
hepatocytes. Consistent with the observations presented in this thesis, Geisterfer et al. 
reported peak IL-6 serum levels as late as 12 hours after turpentine injection in rats [150]. 
Furthermore, in IL-1β knock out mice, turpentine could not elicit a significant increase of 
plasma IL-6 levels and acute phase protein synthesis [152]. 
 
The finding of abolished SOCS3 expression in IL-6-deficient mice confirms the necessity of 
IL-6 for turpentine-driven SOCS3 induction. It also gives evidence that no other turpentine-
released cytokines can compensate for the absence of IL-6. In other words, besides IL-6, IL-
1β, the major cytokine released after administration of turpentine induces SOCS3 only 
indirectly via IL-6 during inflammation in vivo. This conclusion is consistent with the in vitro 
data presented in the first part of this thesis.  
4.7 The role of IL-6 in the systemic inflammation model in vivo 
Whereas turpentine mainly acts via IL-1β and IL-6, endotoxin-mediated inflammation is 
elicited by a wider spectrum of cytokines. TNF-α is the earliest cytokine induced by LPS and 
a major factor conferring endotoxin sensitivity [153] and APP synthesis [154]. TNF-α, like 
IL-1β and IL-6 has also been described to induce SOCS3 expression [113, 155, 156]. 
Additionally, it has been shown that LPS directly induces SOCS3 by signalling through TLR4 
[107, 145]. Although a variety of SOCS3-inducing mechanisms exists, SOCS3 expression 
was severely impaired in LPS-stimulated IL-6-deficient mice. This finding also reveals a 
difference between SOCS3 and APP regulation during bacterial LPS-mediated inflammation: 
with regard to the hepatic expression of APPs other cytokines compensate for the lack of IL-6 
[28, 29], but not with regard to SOCS3 expression. The finding in IL-6 and TNF receptor 1 
double knock out mice (figure 3.2.4) suggests that the main contribution to SOCS3 expression 
at later time points after LPS injection stems from TNF-α signalling and not from direct TLR 
signalling. 
 
Despite the beneficial effects of IL-6 on the restoration of liver homeostasis [157-160], 
overshooting IL-6 signalling has been shown to promote the development of a number of 
diseases, such as autoimmune arthritis, inflammatory bowel disease (reviewed in [77]), 
formation of liver adenomas [161, 162] and liver fibrosis [157]. Data on fibrosis exemplify 
the importance of well-adjusted IL-6 levels: as in the absence of IL-6 [158] or gp130 [160] 
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the development of CCl4-induced liver fibrosis is accelerated, so it is when IL-6 blood levels 
are chronically increased due to concomitant stimulation with turpentine [163]. Uncontrolled 
IL-6 signalling is prevented by induction of SOCS3 [111]. The studies using both models of 
aseptic and endotoxin-induced inflammation reveal a crucial role of IL-6 itself in the hepatic 
expression of SOCS3 during acute inflammatory processes in vivo. Although other cytokines 
are capable of inducing SOCS3, their contribution during inflammation seems to be minor 
with only TNF-α signalling being of significance for the SOCS3 expression at later time 
points after stimulation with LPS. At least in this context, the control of IL-6 signalling does 
not appear to be achieved via activation of additional signalling pathways but primarily via 
direct feedback-induction of SOCS3. 
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5 Outlook 
Based on the results obtained in this thesis, several interesting issues have to be addressed. 
Further investigations are needed to answer the following questions: 
5.1 How does NF-κB activation contribute to the enhancing effect of IL-1β 
on IL-6-induced SOCS3 expression?  
The data presented in this thesis clearly demonstrate that NF-κB is essential for the enhancing 
effect of IL-1β on IL-6-induced SOCS3 expression. Although the results suggest that NF-κB 
act through the induction of downstream effectors to enhance SOCS3 transcripition, the exact 
molecular mechanism for this process is not completely understood. Screening the early 
responsive genes after IL-1β stimulation would provide some hints towards the identification 
of the downstream effectors of NF-κB involved in the enhancing effect of IL-1β on IL-6-
induced SOCS3 expression. NF-κB is composed of homo- and heterodimeric complexes of 
Rel family proteins, which are characterized by an N-terminal RHD (Rel homology domain). 
There are five members in mammals namely RelA (p65), Rel-B, C-Rel, p50 and p52. 
Although so far no direct NF-κB binding to the SOCS3 promoter region investigated has been 
found when antibodies against p65 were applied in CHIP and EMSA assays, the possibility 
that other members of NF-κB family bind to the SOCS3 promoter could not be ruled out. To 
test this possibility, multiple antibodies against the different members of NF-κB family 
should be applied in the ChIP assays and much wider regions within the SOCS3 promoter 
need to be looked at. 
5.2 How does IL-1β increase the mRNA stability of SOCS3? 
The data presented in this thesis demonstrate that SOCS3 mRNA is stabilized by IL-1β. 
However, the molecular mechanism through which IL-1β stabilizes the SOCS3 mRNA is not 
clear. The rate of mRNA degradation is an important determinant of the extent and duration 
of gene expression. In particular, the turnover of mRNA can be modulated by endogenous and 
exogenous signals acting on specific sequences within mRNA [164, 165]. AU rich elements 
(AREs), located in the 3´untranslated region (3´UTR) of a variety of short-lived mRNAs 
found for cytokines and protooncogenes, are the best characterized elements among various 
cis-acting destablizing elements identified so far. The destabilizing function of ARE is 
believed to be regulated by factors with specific ARE binding activities. A plethora of ARE 
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binding proteins has been identified including AUF1, HuR, TIA-1 and tristetraproline (TTP). 
These proteins either promote mRNA degradation, as demonstrated for AUF1, TTP, and TIA-
1, or as in the case of HuR, increase the mRNA stability. Recently, BRF1 (butyrate response 
factor-1), a zinc finger protein homologous to tristetraprolin, has been suggested to target 
most , if not all, mRNAs bearing ARE elements to degradation [166].  
 
The phenomenon which makes the stimulated cells refractory to a second stimulus is defined 
as desensitization. Recently SOCS3 has been suggested to mediate IL-6-induced 
desensitization [167]. Both SOCS3 protein and mRNA display extremely short half-lives 
allowing cells to become sensitive to cytokine stimulation in vivo. Thus, it is of great interest 
to identify the cis-element in the SOCS3 mRNA and the trans-acting factors responsible for 
the fast decay of SOCS3 mRNA. It appears that SOCS3 mRNA possesses several AREs in 
the 3´UTR. Currently we are working on the identification of AREs in SOCS3 mRNA in the 
BRF1-deficient cells (Slow C cells). A number of ARE-containing mRNAs such as mRNAs 
of IL-6 and IL-8 have been shown to be stabilized by the activation of p38 and its 
downstream effector molecule MAP kinase-activated protein kinase 2 (MK2) [168, 169]. 
Since IL-1β is a strong p38 activator, the question arises whether the activation of p38 
pathway mediates the stabilizing effect of IL-1β on IL-6-induced SOCS3 mRNA. In the 
presented thesis, it is shown that the blockade of IL-6-initiated p38 activation with a specific 
inhibitor reduced the SOCS3 expression (figure 3.1.8 A and B) suggesting the p38 pathway to 
contribute to the SOCS3 induction. However, the question whether the contribution of p38 to 
SOCS3 expression relies on an increase of SOCS3 mRNA stability remains to be answered, 
an interesting problem to be solved in the near future.  
5.3 Does IL-1β facilitate the remodeling and decondensation of chromatin 
containing the SOCS3 promoter? 
It is generally accepted that transcription is regulated by nucleosome remodeling and 
chromatin decondensation. Nucleosome remodeling and the decondensation of high-order 
chromatin structure rely on the activities of two classes of multi-protein complexes: ATP-
dependent nucleosome remodeling complexes and histone modification complexes. Recent 
data reveal that upon cytokine stimulation, IKKα can be recruited to the IL-8 promoter and 
direct the phosphorylation of histone H3 on serine 10. The nuclear role of IKKα in modifying 
histone function has been suggested to be critical for the activation of NF-κB-directed gene 
expression [170, 171]. In the presented thesis, a synergistic effect of IL-1β and IL-6 on 
Outlook 
 
 74
SOCS3 expression was observed. Whether IKKα is recruited to the SOCS3 promoter after IL-
1β stimulation is unknown. Thus, it is intriguing to speculate that the signal propagated from 
IL-1β might facilitate chromatin decondesation and nucleosome remodeling. This could be 
achieved by modification of the histones or recruitment of more transcriptional co-activators 
to the promoter. To test this possibility, antibodies against p300/CBP, acetylated histones, 
phosphorylated histones and IKKα can be used in the ChIP assay. To determine whether IL-
1β facilitates nucleosome remodeling, one could compare the nucleosome state after IL-6 
stimulation with that after IL-6/IL-1β costimulation. Currently, we are investigating this issue 
with nucleosome protection assays. 
5.4 How do non-JAK-STAT activators induce SOCS3 expression? 
SOCS3 is believed to be regulated at the transcriptional level in a STAT-dependent manner 
[118]. The in vivo data presented in this thesis strongly argue that IL-6 is the essential factor 
for the induction of SOCS3 in two different models of inflammation. However, some residual 
expression of SOCS3 in IL-6-/- mice in response to LPS challenge was observed (figures 
3.2.1B and 3.2.2B). The SOCS3 expression in IL-6-/- mice upon LPS treatment is likely due to 
TNF-α effect in macrophages since TNFR1-/-IL-6-/- displays totally abolished SOCS3 mRNA 
induction (figure 3.2.4). Consistent with these results, Dalpke et al. [145] and Bode et al. 
[113] could show LPS and TNF-α, non-JAK-STAT activators, induce SOCS3 in 
macrophages. Very recently, Baetz et al. showed that the induction of SOCS3 in response to 
LPS is MyD88-dependent and not the secondary effect of secreted IFN-β [107]. While it is 
conceivable that the regulation of SOCS3 induction occurs at the transcriptional level, the 
precise mechanism of SOCS3 induction by non-JAK-STAT activators remains elusive. 
 
Besides STAT factors, other transcription factors have been suggested to mediate SOCS 
induction. For example, recently Egr-1, an early response transcription factor, has been shown 
to mediate the SOCS1 induction after LPS stimulation [120]. Whether SOCS3 induction by 
LPS is regulated in a similar manner as SOCS1 needs to be investigated. In addition, it has 
been shown by Canfield et al. that IL-4 induces SOCS3 induction in B cells dependent on the 
activation of p38 but not on the activation of STAT6 [122]. The authors hypothesized that the 
transcription factors ATF-2 and Elk-1 are involved in this induction. To confirm this 
hypothesis, further studies need to be done. Regarding the mechanism of SOCS3 induction by 
non-JAK-STAT activators, another possibility could be that LPS and TNF-α stabilize the 
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basal transcripts. It is plausible to speculate that p38 is involved in this potential process. To 
clarify the role of p38 on SOCS3 induction, further investigations are needed.
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6 Summary 
Interleukin-6 (IL-6) exerts pro- as well as anti-inflammatory activities in response to 
infection, injury or other stimuli which affect the homeostasis of the organism. IL-6-induced 
expression of acute phase protein genes in the liver is tightly regulated through both IL-6-
induced feedback inhibitors and the activity of pro-inflammatory cytokines such as tumor 
necrosis factor α and interleukin-1β. In previous studies mechanisms of how IL-1β 
counteracts IL-6-dependent acute phase protein gene induction have been proposed. Apart 
from negatively regulating the IL-6-type cytokine signalling pathways, SOCS3 is also 
essential for regulating many immunological processes. In the first part of this thesis, we 
analyzed how IL-1β regulates IL-6-induced SOCS3 expression. In hepatocytes IL-1β alone 
does not induce SOCS3 expression but it counteracts SOCS3-promoter activation in long term 
studies (>3h). Surprisingly, short term stimulation (around 50 minutes) revealed IL-1β to be a 
potent enhancer of SOCS3 expression in concert with IL-6. This activity of IL-1β depends 
neither on IL-1β-induced p38 MAPKs activity nor on IL-1β-dependent STAT1-serine 
phosphorylation, but on NF-κB-mediated gene induction. Most importantly, we found IL-6-
induced SOCS3 mRNA to be stabilized by the signal propagated from IL-1β. Such a 
regulatory network allows IL-1β to counteract IL-6-dependent expression of acute phase 
protein genes without inhibiting IL-6-induced SOCS3 expression. Moreover, it provides a 
sophisticated mechanism for the IL-1β-dependent inhibition of acute phase protein gene 
induction since reduced SOCS3 expression would lead to enhanced IL-6 activity. 
 
Several signalling pathways have been shown to converge on SOCS3, thereby allowing an 
extensive cross-talk. However, the individual contribution of each cytokine to the induction of 
SOCS3 during the inflammatory processes in vivo is not clear. Using IL-6-deficient mice in 
two well-established animal models of bacterial (LPS) and aseptic (turpentine) inflammation, 
a central role of IL-6 on hepatic expression of SOCS3 during inflammatory processes was 
uncovered and is described in the second part of this thesis. 
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